<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ertapenem: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="uptodate_assets/main.css" rel="stylesheet">


            <section class3D"course-details-area ptb-60">
            <div class3D"container">

                  <div class3D"uptodate2" 3D"padding:50px 0px 50px 0
px;direction: ltr;text-align: left;">
                                          <h1 3D"text-align:center">Ertapenem: Drug information</h1>
                        <div id3D"topicContent" class3D"utdArticleSection
 utdStyle"><div id3D"drugTitle">Ertapenem: Drug information</div><div clas
s3D"clear"></div><div id3D"topicText">(For additional information <a data
-topicid3D"11365" class3D"drug drug_patient" rel3D"external" href3D"htt
ps://medilib.ir/uptodate/show/11365.html">see "Ertapenem: Patient drug informati
on"</a> and <a data-topicid3D"12903.html" class3D"drug drug_pediatric" rel3D"
external" href3D"/d/html/12903">see "Ertapenem: P
ediatric drug information"</a>)<br><br>For abbreviations, symbols, and age 
group definitions used in Lexicomp (<a class3D"graphic graphic_table" rel
3D"external" href3D"/d/html/57469.html">show table</a
>)<div id3D"formulinkBodyPlaceholder" class3D"visuallyHidden drugH1Div"><
span class3D"drugH1"></span></div>
<div id3D"F166533" class3D"list ubnlist drugH1Div drugBrandNames"><span c
lass3D"drugH1">Brand Names: US</span>
                  <ul>
                     <li>INVanz</li></ul></div>
<div id3D"F52866777" class3D"list canbnlist drugH1Div drugBrandNames"><sp
an class3D"drugH1">Brand Names: Canada</span>
                  <ul>
                     <li>INVanz</li></ul></div>
<div id3D"F166557" class3D"ex_sect_xr thclist drugH1Div drugBrandNames"><
span class3D"drugH1">Pharmacologic Category</span>
                  <ul>
                     <li>
                        Antibiotic, Carbapenem</li></ul></div>
<div id3D"F166537" class3D"block doa drugH1Div"><span class3D"drugH1">Do
sing: Adult</span>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Dosage guidance: </b></p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <b>Clinical considerations:</b> Generally reserved for
 pathogens that are resistant to other antibiotics (eg, extended-spectrum b
eta-lactamaseE28093producing organisms) (<span class3D"ref-callout-list
"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-
ref-Munoz-Price.1']" aria-label3D"list of references">Ref</a></span>). Ert
apenem lacks activity against <i>Pseudomonas aeruginosa</i> (unlike other c
arbapenems).</p>
                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"b74db564-f66e-4f55-8b58-97
59dc214a0c" class3D"collapsible-indication-title">Bite wound infection, tr
eatment</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Bite wound infection, treatment (animal or hu
man bite) (alternative agent) (off-label use):</b>
                           <b>IV:</b> 1 g once daily. Duration of treatment
 for established infection (which may include oral step-down therapy) is ty
pically 5 to 14 days and varies based on patient-specific factors, includin
g clinical response (<span class3D"ref-callout-list"><a class3D"ref-callo
ut-list-link" lexi-content-ref-id3D"['lexi-content-ref-Baddour.1','lexi-co
ntent-ref-Baddour.2','lexi-content-ref-24947530']" aria-label3D"list of re
ferences">Ref</a></span>).</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"8f9ec9fd-fc1b-4a1f-868a-ee
b97c396e6e" class3D"collapsible-indication-title">Bloodstream infection</s
pan>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Bloodstream infection (pathogen-directed ther
apy for susceptible gram-negative organisms) (off-label use):</b>
                           <b>IV:</b> 1 g once daily (<span class3D"ref-ca
llout-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lex
i-content-ref-19489710']" aria-label3D"list of references">Ref</a></span>)
. Duration is 7 to 14 days, depending on source and extent of infection, as
 well as clinical response; a 7-day duration is recommended for patients wi
th uncomplicated Enterobacteriaceae bacteremia who respond appropriately to
 antibiotic therapy (<span class3D"ref-callout-list"><a class3D"ref-callo
ut-list-link" lexi-content-ref-id3D"['lexi-content-ref-Moehring.1','lexi-c
ontent-ref-30535100']" aria-label3D"list of references">Ref</a></span>).</
p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"1d3e4522-e8bc-4496-b3e0-f1
fcdd0f13d7" class3D"collapsible-indication-title">Diabetic foot infection,
 moderate to severe</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Diabetic foot infection, moderate to severe:<
/b>
                           <b>IM, IV:</b> 1 g once daily. Duration (which m
ay include oral step-down therapy) is usually 2 to 4 weeks in the absence o
f osteomyelitis but varies based on patient-specific factors, including cli
nical response (<span class3D"ref-callout-list"><a class3D"ref-callout-li
st-link" lexi-content-ref-id3D"['lexi-content-ref-22619242','lexi-content-
ref-Weintrob.1']" aria-label3D"list of references">Ref</a></span>).</p></d
iv>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"c9474c76-c81a-48ef-b80f-72
ce1a0e25f5" class3D"collapsible-indication-title">Intra-abdominal infectio
n, mild to moderate, community-acquired in patients without risk factors fo
r resistance or treatment failure</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Intra-abdominal infection, mild to moderate, 
community-acquired in patients without risk factors for resistance or treat
ment failure (alternative agent):</b></p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <b>Note:</b> Reserve for patients unable to take
 first-line agents (eg, piperacillin/tazobactam) (<span class3D"ref-callou
t-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-co
ntent-ref-Barshak.1']" aria-label3D"list of references">Ref</a></span>).</
p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Cholecystitis, acute:</i>
                           <b>IV:</b> 1 g once daily; continue for 1 day af
ter gallbladder removal or until clinical resolution in patients managed no
noperatively (<span class3D"ref-callout-list"><a class3D"ref-callout-list
-link" lexi-content-ref-id3D"['lexi-content-ref-29090866','lexi-content-re
f-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1']" aria
-label3D"list of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Other intra-abdominal infections (eg, perfora
ted appendix, appendiceal abscess, cholangitis, diverticulitis):</i>
                           <b>IM, IV:</b> 1 g once daily. Total duration of
 therapy (which may include transition to oral antibiotics) is 4 to 5 days 
following adequate source control (<span class3D"ref-callout-list"><a clas
s3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-25992
746','lexi-content-ref-28085573']" aria-label3D"list of references">Ref</a
></span>). For diverticulitis or uncomplicated appendicitis managed without
 intervention, duration is 10 to 14 days (<span class3D"ref-callout-list">
<a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-re
f-Barshak.1','lexi-content-ref-Pemberton.1']" aria-label3D"list of referen
ces">Ref</a></span>); for perforated appendicitis managed with laparoscopic
 appendectomy, 2 to 4 days may be sufficient (<span class3D"ref-callout-li
st"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-conten
t-ref-36669519','lexi-content-ref-25992746']" aria-label3D"list of referen
ces">Ref</a></span>).</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"3c92ca38-0c20-4ec4-b5f0-11
3c6ccf7cd2" class3D"collapsible-indication-title">Osteomyelitis and/or dis
citis</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Osteomyelitis and/or discitis (pathogen-direc
ted therapy for susceptible gram-negative organisms) (off-label use): IV:</
b> 1 g once daily, generally for E289A56 weeks depending on patient-spec
ific factors, such as extent of infection, debridement, and clinical respon
se. Shorter courses are appropriate if the affected bone is completely rese
cted (eg, by amputation) (<span class3D"ref-callout-list"><a class3D"ref-
callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-26229122','lex
i-content-ref-osmon.2019']" aria-label3D"list of references">Ref</a></span
>).</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"fb013f00-067f-48b7-8802-31
7acc3d010f" class3D"collapsible-indication-title">Pelvic infections, acute
</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Pelvic infections, acute (eg, postpartum and 
postsurgical gynecologic infections) (alternative agent):</b>
                           <b>IM, IV:</b> 1 g once daily; duration of thera
py varies based on type of infection.</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"7792e77c-7758-4230-a81e-dc
7dd3a6acb9" class3D"collapsible-indication-title">Pneumonia</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Pneumonia (alternative agent):</b></p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <b>
                              <i>Community-acquired pneumonia, empiric ther
apy (inpatients without risk factors for </i>
                              <i>Pseudomonas aeruginosa</i>
                              <i>):</i> IM, IV:</b> 1 g once daily as part 
of an appropriate combination regimen. Duration (which may include oral ste
p-down therapy) is for a minimum of 5 days; patients should be clinically s
table with normal vital signs before therapy is discontinued (<span class
3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-content-ref-i
d3D"['lexi-content-ref-File.1','lexi-content-ref-31573350']" aria-label3D
"list of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>
                              <b>Hospital-acquired pneumonia or ventilator-
associated pneumonia (pathogen-directed therapy for extended-spectrum beta-
lactamase-producing organisms) (off-label use):</b></i>
                           <b>IV:</b> 1 g once daily (<span class3D"ref-ca
llout-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lex
i-content-ref-17540673']" aria-label3D"list of references">Ref</a></span>)
. Duration of therapy varies based on disease severity and response to ther
apy; treatment is typically given for 7 days (<span class3D"ref-callout-li
st"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-conten
t-ref-klompas.2019']" aria-label3D"list of references">Ref</a></span>).</p
></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"9d1b4c51-5035-4766-b50d-dd
4e58990353" class3D"collapsible-indication-title">Prosthetic joint infecti
on</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Prosthetic joint infection (pathogen-directed
 therapy for susceptible gram-negative organisms) (off-label use): IV:</b> 
1 g every 24 hours; duration varies, but is generally 4 to 6 weeks for pati
ents who undergo resection arthroplasty (<span class3D"ref-callout-list"><
a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref
-23223583']" aria-label3D"list of references">Ref</a></span>).</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"5389b037-d8ce-48e2-98b3-f8
bb5a208a34" class3D"collapsible-indication-title">Skin and soft tissue inf
ection, moderate to severe</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Skin and soft tissue infection, moderate to s
evere:</b></p>
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Note:</b> For patients with select surgical s
ite infections (intestinal, GU tract), necrotizing infections, or patients 
with or at risk for pathogens resistant to other agents (<span class3D"ref
-callout-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['
lexi-content-ref-24947530','lexi-content-ref-Stevens.1']" aria-label3D"lis
t of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>IV:</b> 1 g once daily; often used as part of
 an appropriate combination regimen. Usual duration (including oral step-do
wn therapy) is 5 to 14 days based on severity and clinical response; for ne
crotizing infections, continue until further debridement is not necessary a
nd the patient has improved clinically and is afebrile for 48 to 72 hours (
<span class3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-co
ntent-ref-id3D"['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']"
 aria-label3D"list of references">Ref</a></span>).</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"fa7b6aef-11c5-4b72-97a0-a3
9f0f808184" class3D"collapsible-indication-title">Surgical prophylaxis</sp
an>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Surgical prophylaxis (colorectal surgery) (al
ternative agent):</b>
                           <b>IV:</b> 1 g within 60 minutes prior to surgic
al incision (<span class3D"ref-callout-list"><a class3D"ref-callout-list-
link" lexi-content-ref-id3D"['lexi-content-ref-23327981']" aria-label3D"l
ist of references">Ref</a></span>). <b>Note:</b> Postoperative prophylaxis 
is not recommended in clean and clean-contaminated surgeries (<span class
3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-content-ref-i
d3D"['lexi-content-ref-28467526']" aria-label3D"list of references">Ref</
a></span>). Some experts recommend against using ertapenem for surgical pro
phylaxis out of concern for inducing resistance (<span class3D"ref-callout
-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-con
tent-ref-Anderson.1']" aria-label3D"list of references">Ref</a></span>).</
p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"c3dbb92e-1e0f-40e8-92cb-d0
cf047a674d" class3D"collapsible-indication-title">Urinary tract infection,
 complicated</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Urinary tract infection, complicated (pyelone
phritis or urinary tract infection with systemic signs/symptoms) (alternati
ve agent): </b></p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Inpatients: </i>
                           <b>IV, IM:</b> 1 g once daily. Switch to an appr
opriate oral regimen once symptoms improve, if culture and susceptibility r
esults allow. Total duration of therapy ranges from 5 to 14 days and depend
s on clinical response and the antimicrobial chosen to complete the regimen
 (<span class3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-
content-ref-id3D"['lexi-content-ref-Hooton.1','lexi-content-ref-21292654',
'lexi-content-ref-15150185']" aria-label3D"list of references">Ref</a></sp
an>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Outpatients:</i>
                           <b>IV, IM:</b> 1 g as a single dose, followed by
 5 to 14 days of appropriate oral therapy.<b> Note: </b>For patients who ar
e systemically ill, at risk for more severe illness, or at risk for multidr
ug-resistant infection, some experts continue daily parenteral therapy pend
ing culture and susceptibility testing results (<span class3D"ref-callout-
list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-cont
ent-ref-Hooton.1']" aria-label3D"list of references">Ref</a></span>).</p><
/div>
</div>
</div>
<div id3D"F50990673" class3D"block dora drugH1Div"><span class3D"drugH1"
>Dosing: Kidney Impairment: Adult</span>
                  <p 3D"text-indent:0em;display:inline">The renal dos
ing recommendations are based upon the best available evidence and clinical
 expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF;
 Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung
, MD, MS.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Altered kidney function: IM, IV:</b></p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <b>Note:</b> Although the manufacturerE28099s label
ing reports CrCl units as mL/minute/1.73 m<sup>2</sup>, it is not necessary
 to adjust CrCl estimates for BSA when dosing ertapenem, as renal clearance
 of a drug is proportional to an individualE28099s estimated CrCl in mL/
minute, and ertapenem is generally well tolerated (Nix 2017; expert opinion
).</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">CrCl &gt;3
0 mL/minute: No dosage adjustment necessary.</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">CrCl E2
89A430 mL/minute: 500 mg once daily.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Hemodialysis, intermittent (thrice weekly):</b></p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <i>Daily dosing:</i>
                     <b>IM, IV: </b>500 mg once daily. When scheduled dose 
falls on a hemodialysis day, administer at least 6 hours prior to hemodialy
sis or wait until after hemodialysis; however, if the dose is given within 
6 hours prior to hemodialysis, a supplementary dose of 150 mg is required f
ollowing hemodialysis.</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <i>Three times weekly (post hemodialysis) dosing:</i>
                     <b>IM, IV:</b> 500 mg or 1 g 3 times weekly after hemo
dialysis on hemodialysis days (<span class3D"ref-callout-list"><a class3D
"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-24060141'
,'lexi-content-ref-29992286','lexi-content-ref-31527026']" aria-label3D"li
st of references">Ref</a></span>).</p>
                  <p 3D"text-indent:-2em;margin-left:6em;">
                     <b>Note:</b> Consider patient-specific factors such as
 body weight, infection severity, and residual kidney function when decidin
g between doses (<span class3D"ref-callout-list"><a class3D"ref-callout-l
ist-link" lexi-content-ref-id3D"['lexi-content-ref-Expert.1']" aria-label
3D"list of references">Ref</a></span>).</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Peritoneal dialysis: IM, IV:</b> 500 mg once daily 
(<span class3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-c
ontent-ref-id3D"['lexi-content-ref-22083473']" aria-label3D"list of refer
ences">Ref</a></span>).</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>CRRT:</b> Drug clearance is dependent on the efflue
nt flow rate, filter type, and method of renal replacement. Recommendations
 were developed through Monte Carlo simulation only and based on high-flux 
dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,00
0 mL/hour) unless otherwise noted. Appropriate dosing requires consideratio
n of adequate drug concentrations (eg, site of infection), organism minimum
 inhibitory concentration (MIC), and residual kidney function. Close monito
ring of response and adverse reactions (eg, neurotoxicity) due to drug accu
mulation is important.</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <b>IM, IV: </b>1 g once daily (<span class3D"ref-call
out-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-
content-ref-24323468']" aria-label3D"list of references">Ref</a></span>).<
/p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>PIRRT (eg, sustained, low-efficiency diafiltration)
:</b> Drug clearance is dependent on the effluent flow rate, filter type, a
nd method of renal replacement. Recommendations are based on daily treatmen
ts with 4 to 5 L/hour (<span class3D"ref-callout-list"><a class3D"ref-cal
lout-list-link" lexi-content-ref-id3D"['lexi-content-ref-26919659']" aria-
label3D"list of references">Ref</a></span>) or 10 L/hour (Burkhardt 2009) 
of dialysate/ultrafiltrate flow rate for each 8- to 10-hour session. Approp
riate dosing requires consideration of adequate drug concentrations (eg, si
te of infection), organism MIC, and residual kidney function. Close monitor
ing of response and adverse reactions (eg, neurotoxicity) due to drug accum
ulation is important.</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <b>IM, IV: </b>500 mg initially, then 500 mg post each
 PIRRT session or 1 g once daily (<span class3D"ref-callout-list"><a class
3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-187238
63','lexi-content-ref-26919659']" aria-label3D"list of references">Ref</a>
</span>).</p></div>
<div id3D"F50987937" class3D"block doha drugH1Div"><span class3D"drugH1"
>Dosing: Hepatic Impairment: Adult</span>
                  <p 3D"text-indent:0em;display:inline">Adjustments c
annot be recommended (lack of experience and research in this patient popul
ation).</p></div>
<div id3D"F166538" class3D"block doe drugH1Div"><span class3D"drugH1">Do
sing: Older Adult</span>
                  <p 3D"text-indent:0em;display:inline">Refer to adul
t dosing.</p></div>
<div id3D"F166549" class3D"block dop drugH1Div"><span class3D"drugH1">Do
sing: Pediatric</span><p>(For additional information <a data-topicid3D"129
03" class3D"drug drug_pediatric" rel3D"external" href3D"https://medilib.
ir/uptodate/show/12903">see "Ertapenem: Pediatric drug information"</a>)</p
>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Dosage guidance:</b></p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <b>Clinical considerations:</b> Due to limited clinica
l data, ertapenem is usually reserved for extended-spectrum beta-lactamase 
infections with urinary sources or soft tissue infections when adequate sou
rce control has been achieved (<span class3D"ref-callout-list"><a class3D
"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-24501388'
]" aria-label3D"list of references">Ref</a></span>). Ertapenem lacks activ
ity against <i>Pseudomonas aeruginosa</i> (unlike other carbapenems).</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>General dosing, susceptible infection</b> (<span cl
ass3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-content-re
f-id3D"['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" aria-label
3D"list of references">Ref</a></span>):</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Infants an
d Children: IM, IV: 15 mg/kg/dose twice daily; maximum dose: 500 mg/dose.</
p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Adolescent
s: IM, IV: 1,000 mg once daily.</p>
                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"02b4604f-7121-4a88-88dd-a5
008cafb941" class3D"collapsible-indication-title">Intra-abdominal infectio
n, complicated</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Intra-abdominal infection, complicated:</b>
                           <b>Note:</b> Guidelines recommend a treatment du
ration of 4 to 7 days (provided source controlled) for community-acquired, 
mild to moderate infections(<span class3D"ref-callout-list"><a class3D"re
f-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-20034345']" 
aria-label3D"list of references">Ref</a></span>); manufacturer labeling su
ggests a duration of 5 to 14 days; however, longer durations (&gt;7 days) h
ave not been associated with improved outcomes (<span class3D"ref-callout-
list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-cont
ent-ref-20034345']" aria-label3D"list of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Infa
nts E289A53 months and Children: IM, IV: 15 mg/kg/dose twice daily; maxi
mum dose: 500 mg/dose.</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Adol
escents: IM, IV: 1,000 mg once daily.</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"fb013f00-067f-48b7-8802-31
7acc3d010f" class3D"collapsible-indication-title">Pelvic infections, acute
</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Pelvic infections, acute:</b></p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Infa
nts E289A53 months and Children: IM, IV: 15 mg/kg/dose twice daily for 3
 to 10 days based on severity of infection; maximum dose: 500 mg/dose.</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Adol
escents: IM, IV: 1,000 mg once daily for 3 to 10 days based on severity of 
infection.</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"ed599b2f-52de-47cd-b7d2-d7
06008b1db0" class3D"collapsible-indication-title">Pneumonia, community-acq
uired</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Pneumonia, community-acquired:</b>
                           <b>Note:</b> Guidelines suggest a usual duration
 of therapy of 10 days (including both parental and possible switch to appr
opriate oral step-down therapy); however, longer duration may be necessary 
for some organisms and/or complicated infections (<span class3D"ref-callou
t-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-co
ntent-ref-21880587']" aria-label3D"list of references">Ref</a></span>).</p
>
                        <p 3D"text-indent:-2em;margin-left:4em;">Infa
nts E289A53 months and Children: IM, IV: 15 mg/kg/dose twice daily for 1
0 to 14 days; maximum dose: 500 mg/dose.</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Adol
escents: IM, IV: 1,000 mg once daily for 10 to 14 days.</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"0baa4e1c-eea5-4294-8e1c-6a
5d955a0d21" class3D"collapsible-indication-title">Skin and skin structure 
infection, complicated or necrotizing</span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Skin and skin structure infection, complicate
d or necrotizing:</b>
                           <b>Note</b>: For complicated infection, continue
 therapy for 7 to 14 days. For necrotizing infection, use in combination wi
th an agent effective against MRSA (eg, vancomycin, linezolid, daptomycin) 
for empiric therapy of polymicrobial (mixed) infections. Continue until fur
ther debridement is not necessary, patient has clinically improved, and pat
ient is afebrile for 48 to 72 hours (<span class3D"ref-callout-list"><a cl
ass3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-249
47530']" aria-label3D"list of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Infa
nts E289A53 months and Children: IM, IV: 15 mg/kg/dose twice daily; maxi
mum dose: 500 mg/dose.</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Adol
escents: IM, IV: 1,000 mg once daily.</p></div>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"fa7b6aef-11c5-4b72-97a0-a3
9f0f808184" class3D"collapsible-indication-title">Surgical prophylaxis</sp
an>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Surgical prophylaxis:</b> Limited data availa
ble: Children and Adolescents: IV: 15 mg/kg within 60 minutes prior to surg
ical incision; maximum dose: 1,000 mg/dose (<span class3D"ref-callout-list
"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-
ref-23327981']" aria-label3D"list of references">Ref</a></span>).</p></div
>
</div>

                  <div class3D"collapsible-indication">
                     <span data-indication-id3D"5ac615e6-688a-461c-8a9f-5e
7703d06ac9" class3D"collapsible-indication-title">Urinary tract infection<
/span>
                     <div class3D"collapsible-indication-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">
                           <b>Urinary tract infection (including pyelonephr
itis):</b>
                           <b>Note:</b> Duration includes possible switch t
o appropriate oral therapy after at least 3 days of parenteral treatment, o
nce clinical improvement demonstrated.</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Infa
nts E289A53 months and Children: IM, IV: 15 mg/kg/dose twice daily for 1
0 to 14 days; maximum dose: 500 mg/dose.</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Adol
escents: IM, IV: 1,000 mg once daily for 10 to 14 days.</p></div>
</div>
</div>
<div id3D"F51128325" class3D"block dorp drugH1Div"><span class3D"drugH1"
>Dosing: Kidney Impairment: Pediatric</span>
                  <p 3D"text-indent:0em;">There are no pediatric spec
ific recommendations; based on experience in adult patients, dosage adjustm
ent suggested.</p></div>
<div id3D"F51108681" class3D"block dohp drugH1Div"><span class3D"drugH1"
>Dosing: Hepatic Impairment: Pediatric</span>
                  <p 3D"text-indent:0em;display:inline">There are no 
dosage adjustments provided in the manufacturer's labeling; has not be adeq
uately studied.</p></div>
<div id3D"F58435972" class3D"block arsc drugH1Div"><span class3D"drugH1"
>Adverse Reactions (Significant): Considerations</span>
                  <div class3D"collapsible">
                     <span class3D"collapsible-title">Clostridioides diffi
cile infection</span>
                     <div class3D"collapsible-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">Clos
tridioides difficile infection (CDI) has occurred with ertapenem, including
 <b>
                              <i>Clostridioides difficile</i>-associated di
arrhea</b> (CDAD) and <b>
                              <i>Clostridioides difficile</i> colitis</b>. 
Ertapenem for surgical prophylaxis is associated with an increased incidenc
e of hospital-onset CDI (<span class3D"ref-callout-list"><a class3D"ref-c
allout-list-link" lexi-content-ref-id3D"['lexi-content-ref-17182989','lexi
-content-ref-26278576']" aria-label3D"list of references">Ref</a></span>).
 Ertapenem does not appear to have a higher risk of CDI compared to other c
arbapenems (<span class3D"ref-callout-list"><a class3D"ref-callout-list-l
ink" lexi-content-ref-id3D"['lexi-content-ref-35708330']" aria-label3D"li
st of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Mechanism</i>: Dose- and time-related; potent
ially related to recent or cumulative antibiotic exposure. Ertapenem may ca
use disruption of the intestinal microbiota resulting in the overgrowth of 
pathogens, such as <i>C. difficile </i>(<span class3D"ref-callout-list"><a
 class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-
29689301','lexi-content-ref-29462280','lexi-content-ref-21653301']" aria-la
bel3D"list of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Onset</i>: Varied; often occurs between 5 and
 30 days after initial dose (<span class3D"ref-callout-list"><a class3D"r
ef-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-23871314','
lexi-content-ref-22146873']" aria-label3D"list of references">Ref</a></spa
n>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Risk factors:</i></p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Antibiotic exposure (highest risk factor) (<span class3D"ref-callou
t-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-co
ntent-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','l
exi-content-ref-27216385','lexi-content-ref-29272341']" aria-label3D"list 
of references">Ref</a></span>)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Type of antibiotic (carbapenems among highest risk) (<span class3D"
ref-callout-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D
"['lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-29
462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-conte
nt-ref-29272341']" aria-label3D"list of references">Ref</a></span>)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Long durations in a hospital or other healthcare setting (recent or 
current) (<span class3D"ref-callout-list"><a class3D"ref-callout-list-lin
k" lexi-content-ref-id3D"['lexi-content-ref-CDC.1','lexi-content-ref-29462
280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-
ref-29272341']" aria-label3D"list of references">Ref</a></span>)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Older adults (<span class3D"ref-callout-list"><a class3D"ref-callo
ut-list-link" lexi-content-ref-id3D"['lexi-content-ref-CDC.1','lexi-conten
t-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','le
xi-content-ref-29272341']" aria-label3D"list of references">Ref</a></span>
)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Immunocompromised conditions (<span class3D"ref-callout-list"><a cl
ass3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-CDC
.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-r
ef-27216385','lexi-content-ref-29272341']" aria-label3D"list of references
">Ref</a></span>)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 A serious underlying condition (<span class3D"ref-callout-list"><a 
class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-C
DC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content
-ref-27216385','lexi-content-ref-29272341']" aria-label3D"list of referenc
es">Ref</a></span>)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 GI surgery/manipulation (<span class3D"ref-callout-list"><a class
3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-294622
80','lexi-content-ref-27216385']" aria-label3D"list of references">Ref</a>
</span>)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Antiulcer medications (eg, proton pump inhibitors, H<sub>2</sub> blo
ckers) (<span class3D"ref-callout-list"><a class3D"ref-callout-list-link"
 lexi-content-ref-id3D"['lexi-content-ref-CDC.1','lexi-content-ref-2946228
0','lexi-content-ref-27216385','lexi-content-ref-29272341']" aria-label3D"
list of references">Ref</a></span>)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Chemotherapy (<span class3D"ref-callout-list"><a class3D"ref-callo
ut-list-link" lexi-content-ref-id3D"['lexi-content-ref-CDC.1','lexi-conten
t-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','le
xi-content-ref-29272341']" aria-label3D"list of references">Ref</a></span>
)</p></div>
</div>

                  <div class3D"collapsible">
                     <span class3D"collapsible-title">CNS effects</span>
                     <div class3D"collapsible-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">Carb
apenems, including ertapenem, may cause CNS toxicity. Noteworthy CNS effect
s caused by ertapenem include <b>encephalopathy</b>, <b>altered mental stat
us</b>, <b>hallucinations</b>, and <b>seizures</b> (<span class3D"ref-call
out-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-
content-ref-28203577']" aria-label3D"list of references">Ref</a></span>). 
Ertapenem is associated with a lower seizure risk than other carbapenems, p
otentially due to structural differences at the C-2 position and/or unique 
pharmacokinetic properties, such as small volume of distribution and high p
rotein binding (<span class3D"ref-callout-list"><a class3D"ref-callout-li
st-link" lexi-content-ref-id3D"['lexi-content-ref-7797443']" aria-label3D
"list of references">Ref</a></span>). Resolution to baseline mental status 
after discontinuation often occurs within 2 to 14 days (<span class3D"ref-
callout-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['l
exi-content-ref-21177419','lexi-content-ref-25487647','lexi-content-ref-282
03577','lexi-content-ref-22579271']" aria-label3D"list of references">Ref<
/a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Mechanism: </i>Not clearly established; postu
lated to be due to the antagonism of the GABA<sub>A</sub> receptor binding 
site. A carbapenem with a basic C-2 side chain increases the binding to GAB
A<sub>A </sub>(eg, imipenem) (<span class3D"ref-callout-list"><a class3D"
ref-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-7797443']"
 aria-label3D"list of references">Ref</a></span>). Ertapenem has an acidic
 carboxyl group at the C-2 position and is expected to have the lowest bind
ing to GABA<sub>A</sub>, subsequently reducing its potential for neurotoxic
 activity (<span class3D"ref-callout-list"><a class3D"ref-callout-list-li
nk" lexi-content-ref-id3D"['lexi-content-ref-8383938','lexi-content-ref-28
203577']" aria-label3D"list of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Onset: </i>Varied; signs of neurotoxicity are
 often observed within 5 to 7 days after the initial ertapenem dose (<span 
class3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-content-
ref-id3D"['lexi-content-ref-21177419','lexi-content-ref-28203577']" aria-l
abel3D"list of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Risk factors:</i></p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Preexisting neurologic conditions (eg, brain injury, seizures, strok
e) (<span class3D"ref-callout-list"><a class3D"ref-callout-list-link" lex
i-content-ref-id3D"['lexi-content-ref-21449629']" aria-label3D"list of re
ferences">Ref</a></span>)</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Drug accumulation in kidney impairment or hemodialysis (<span class
3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-content-ref-i
d3D"['lexi-content-ref-32618479','lexi-content-ref-25487647','lexi-content
-ref-21449629']" aria-label3D"list of references">Ref</a></span>)</p></div
>
</div>

                  <div class3D"collapsible">
                     <span class3D"collapsible-title">Hypersensitivity rea
ctions (immediate and delayed)</span>
                     <div class3D"collapsible-wrap">
                        <p 3D"text-indent:-2em;margin-left:2em;">Imme
diate (including <b>anaphylaxis</b> and<b> urticaria</b>) and delayed hyper
sensitivity reactions have been reported. Delayed hypersensitivity reaction
s range from <b>skin rash </b>to rare severe cutaneous adverse reactions (S
CARs), including <b>acute generalized exanthematous pustulosis </b>(AGEP) a
nd <b>drug reaction with eosinophilia and systemic symptoms </b>(<span clas
s3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-content-ref-
id3D"['lexi-content-ref-23886234','lexi-content-ref-31398843']" aria-label
3D"list of references">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Mechanism:</i> NonE28093dose-related; immu
nologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) 
are IgE-mediated. Delayed hypersensitivity reactions, including morbillifor
m drug eruptions (MDE) and SCARs, are generally mediated by T-cells (<span 
class3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-content-
ref-id3D"['lexi-content-ref-30558872','lexi-content-ref-36740326','lexi-co
ntent-ref-26339470']" aria-label3D"list of references">Ref</a></span>).</p
>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Onset: </i>Immediate hypersensitivity reactio
ns: Rapid; IgE-mediated reactions (anaphylaxis, urticaria) generally occur 
within 1 hour of administration but may occur up to 6 hours after exposure 
(<span class3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-c
ontent-ref-id3D"['lexi-content-ref-30558872']" aria-label3D"list of refer
ences">Ref</a></span>). Delayed hypersensitivity reactions: Varied; MDE typ
ically occur ~7 to 10 days after initiation. Other delayed hypersensitivity
 reactions, including SCARs, typically occur days to 8 weeks after drug exp
osure, but may occur more rapidly (usually within 1 to 4 days) upon reexpos
ure (<span class3D"ref-callout-list"><a class3D"ref-callout-list-link" le
xi-content-ref-id3D"['lexi-content-ref-30558872','lexi-content-ref-2612055
2','lexi-content-ref-NICE.1']" aria-label3D"list of references">Ref</a></s
pan>). AGEP has been reported within 2 days after initiation of ertapenem (
<span class3D"ref-callout-list"><a class3D"ref-callout-list-link" lexi-co
ntent-ref-id3D"['lexi-content-ref-23886234']" aria-label3D"list of refere
nces">Ref</a></span>).</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">
                           <i>Risk factors</i>:</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Previous hypersensitivity to carbapenems</p>
                        <p 3D"text-indent:-2em;margin-left:6em;">E2
80A2 Cross-reactivity between penicillins/cephalosporins and carbapenems 
is considered E289A41% (<span class3D"ref-callout-list"><a class3D"ref
-callout-list-link" lexi-content-ref-id3D"['lexi-content-ref-27164625','le
xi-content-ref-25457154','lexi-content-ref-24180646']" aria-label3D"list o
f references">Ref</a></span>)</p>
                        <p 3D"text-indent:-2em;margin-left:8em;">- De
spite similar core structures, cross-reactions between carbapenems have not
 been well described and several case reports of selective immediate or del
ayed reactions to a specific carbapenem with tolerance to another have been
 reported (<span class3D"ref-callout-list"><a class3D"ref-callout-list-li
nk" lexi-content-ref-id3D"['lexi-content-ref-31398843']" aria-label3D"lis
t of references">Ref</a></span>). Ertapenem has been tolerated in a patient
 following a hypersensitivity reaction to meropenem (<span class3D"ref-cal
lout-list"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi
-content-ref-30763732']" aria-label3D"list of references">Ref</a></span>).
</p></div>
</div>
</div>
<div id3D"F166502" class3D"block adr drugH1Div"><span class3D"drugH1">Ad
verse Reactions</span>
                  <p 3D"text-indent:0em;display:inline">The following
 adverse drug reactions and incidences are derived from product labeling un
less otherwise specified. As reported in adults, unless otherwise noted.</p
>
                  <p 3D"text-indent:-2em;margin-left:2em;">&gt;10%: G
astrointestinal: Diarrhea (infants, children, adolescents, adults: 9% to 12
%)</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">1% to 10%:
</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Cardiovasc
ular: Asystole (&lt;2%), atrial fibrillation (&lt;2%), bradycardia (&lt;2%)
, cardiac arrhythmia (&lt;2%), chest pain (infants, children, adolescents, 
adults: &lt;2%), edema (E289A43%), flushing (&lt;2%), heart failure (&lt
;2%), heart murmur(&lt;2%), hypertension (&lt;2%), hypotension (1% to 2%), 
phlebitis (infants, children, adolescents, adults: &lt;2%), syncope (&lt;2%
), tachycardia (&lt;2%), thrombophlebitis (&lt;2%), ventricular tachycardia
 (&lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Dermatolog
ic: Dermatitis (infants, children, adolescents, adults: &lt;2%), desquamati
on (&lt;2%), diaphoresis (&lt;2%), erythema of skin (&lt;2%), erythematous 
rash (infants, children, and adolescents: &lt;2%), pruritus (infants, child
ren, adolescents, adults: E289A42%), skin lesion (infants, children, and
 adolescents: &lt;2%), skin rash (infants, children, adolescents, adults: 2
% to 3%)<span class3D"lexi-table-link-container"> (<a class3D"lexi-table-
link" data-table-id3D"lexi-content-skin-rash" aria-label3D"Skin Rash tabl
e link">table 1</a>)</span><span 3D"display:none;" class3D"table-lin
k">Skin Rash</span>, urticaria (&lt;2%)</p>
                  <table border3D"1" data-table-id3D"Skin Rash" rules3D"
all" id3D"lexi-content-skin-rash" data-hyperlink3D"yes" class3D"lexi-mod
al-content" frame3D"border">
                     <caption 3D"text-align:center;">
                        <b>Ertapenem: Adverse Reaction: Skin Rash</b></capt
ion>
                     <colgroup><col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     </colgroup><thead>
                        <tr>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Drug (Ertapenem)</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Comparator</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Population</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Dose</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Number of Patients (Ertapenem)</b></p><
/th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Number of Patients (Comparator)</b></p>
</th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Comments</b></p></th></tr></thead>
                     <tbody>
                        <tr>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>3%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>2%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Infants, children, and adolescents</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>15 mg/kg twice daily up to a maximum of 1 g daily</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>384</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>100</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Comparator: Ceftriaxone</p></td></tr>
                        <tr>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>3%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>8%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Infants, children, and adolescents</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>15 mg/kg twice daily up to maximum of 1 g daily</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>384</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>24</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Comparator: Ticarcillin and Clavulanate</p></td></tr>
                        <tr>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>3%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>3%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Adults</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>1 g daily</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>802</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>774</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Comparator: Piperacillin and Tazobactam</p></td></tr>
                        <tr>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>2%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>2%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Adults</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>1 g daily</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>1,152</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>942</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Comparator: Ceftriaxone</p></td></tr></tbody></table>
                  <p 3D"text-indent:-2em;margin-left:4em;">Endocrine 
&amp; metabolic: Decreased serum albumin (&lt;2%), decreased serum potassiu
m (&lt;2%), dehydration (&lt;2%), increased serum glucose (&lt;2%), increas
ed serum potassium (&lt;2%), increased serum sodium (&lt;2%), weight loss (
&lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Gastrointe
stinal: Abdominal distention (&lt;2%), abdominal pain (infants, children, a
dolescents, adults: 4% to 5%), acid regurgitation (&lt;2%), anorexia (&lt;2
%), cholelithiasis (&lt;2%), <i>Clostridioides difficile</i>-associated dia
rrhea (&lt;2%), constipation (infants, children, adolescents, adults: 2% to
 4%), decreased appetite (infants, children, and adolescents: &lt;2%), duod
enitis (&lt;2%), dysgeusia (&lt;2%), dyspepsia (&lt;2%), dysphagia (&lt;2%)
, esophagitis (&lt;2%), flatulence (&lt;2%), gastritis (&lt;2%), gastrointe
stinal hemorrhage (&lt;2%), hemorrhoids (&lt;2%), hiccups (&lt;2%), intesti
nal obstruction (&lt;2%), nausea (infants, children, adolescents: &lt;2%; a
dults: 6% to 9%), oral candidiasis (infants, children, adolescents, adults:
 &lt;2%), oral mucosa ulcer (&lt;2%), pancreatitis (&lt;2%), pyloric stenos
is (&lt;2%), sore throat (&lt;2%), stomatitis (&lt;2%), upper abdominal pai
n (infants, children, and adolescents: &lt;2%), vomiting (infants, children
, adolescents, adults: 4% to 10%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Genitourin
ary: Anuria (&lt;2%), bladder dysfunction (&lt;2%), finding of blood in uri
ne (increased red blood cells: 1% to 3%), genital rash (infants, children, 
and adolescents: &lt;2%), hematuria (&lt;2%), oliguria (&lt;2%), proteinuri
a (infants, children, and adolescents: &lt;2%), urinary retention (&lt;2%),
 vaginitis (1% to 3%), vulvovaginal candidiasis (&lt;2%), vulvovaginal prur
itus (&lt;2%), vulvovaginitis (&lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Hematologi
c &amp; oncologic: Decreased hematocrit (3%), decreased hemoglobin (5%), de
creased neutrophils (infants, children, adolescents: 6%; adults: &lt;2%), d
ecreased platelet count (&lt;2%), decreased white blood cell count (infants
, children, adolescents, adults: &lt;2%), eosinophilia (infants, children, 
adolescents, adults: E289A42%), hematoma (&lt;2%), leukocyturia (2% to 3
%), prolonged partial thromboplastin time (&lt;2%), prolonged prothrombin t
ime (&lt;2%), thrombocythemia (infants, children, adolescents: &lt;2%; adul
ts: 4% to 7%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Hepatic: I
ncreased serum alanine aminotransferase (infants, children, adolescents, ad
ults: 4% to 9%), increased serum alkaline phosphatase (infants, children, a
dolescents: &lt;2%; adults: 4% to 7%), increased serum aspartate transamina
se (infants, children, adolescents, adults: 4% to 8%), increased serum bili
rubin (&lt;2%; including increased direct serum bilirubin or increased indi
rect serum bilirubin), jaundice (&lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Hypersensi
tivity: Facial edema (&lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Infection:
 Abscess (abdominal: infants, children, and adolescents: &lt;2%), candidias
is (infants, children, adolescents, adults: &lt;2%), herpes simplex infecti
on (infants, children, and adolescents: &lt;2%), septic shock (&lt;2%), sep
ticemia (&lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Local: Ery
thema at injection site (infants, children, and adolescents: 4%), induratio
n at injection site (infants, children, adolescents, adults: &lt;2%), infus
ed vein complication (5% to 7%), infusion-site pain (infants, children, ado
lescents: 7%), injection-site phlebitis (infants, children, adolescents: &l
t;2%), injection-site pruritus (infants, children, and adolescents: &lt;2%)
, pain at injection site (&lt;2%), swelling at injection site (infants, chi
ldren, and adolescents: &lt;2%), warm sensation at injection site (infants,
 children, and adolescents: &lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Nervous sy
stem: Aggressive behavior (&lt;2%), altered mental status (3% to 5%; includ
ing agitation, confusion, decreased mental acuity, delirium, disorientation
, drowsiness, stupor)<span class3D"lexi-table-link-container"> (<a class
3D"lexi-table-link" data-table-id3D"lexi-content-altered-mental-status" a
ria-label3D"Altered Mental Status table link">table 2</a>)</span><span sty
le3D"display:none;" class3D"table-link">Altered Mental Status</span>, anx
iety (&lt;2%), asthenia (&lt;2%), chills (&lt;2%), depression (&lt;2%), diz
ziness (infants, children, adolescents, adults: E289A42%), fatigue (&lt;
2%), headache (infants, children, adolescents, adults: 4% to 7%), hypoesthe
sia (&lt;2%), hypothermia (infants, children, and adolescents: &lt;2%), ins
omnia (infants, children, adolescents, adults: E289A43%), malaise (&lt;2
%), nervousness (&lt;2%), pain (&lt;2%), paresthesia (&lt;2%), subdural hem
atoma (&lt;2%), tremor (&lt;2%), vertigo (&lt;2%), voice disorder (&lt;2%)<
/p>
                  <table border3D"1" data-table-id3D"Altered Mental Statu
s" rules3D"all" id3D"lexi-content-altered-mental-status" data-hyperlink
3D"yes" class3D"lexi-modal-content" frame3D"border">
                     <caption 3D"text-align:center;">
                        <b>Ertapenem: Adverse Reaction: Altered Mental Stat
us</b></caption>
                     <colgroup><col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     </colgroup><thead>
                        <tr>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Drug (Ertapenem)</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Comparator</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Population</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Dose</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Number of Patients (Ertapenem)</b></p><
/th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Number of Patients (Comparator)</b></p>
</th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Comments</b></p></th></tr></thead>
                     <tbody>
                        <tr>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>5%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>3%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Adults</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>1 g daily</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>802</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>774</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Comparator: Piperacillin and Tazobactam</p></td></tr>
                        <tr>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>3%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>3%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Adults</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>1 g daily</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>1,152</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>942</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Comparator: Ceftriaxone</p></td></tr></tbody></table>
                  <p 3D"text-indent:-2em;margin-left:4em;">Neuromuscu
lar &amp; skeletal: Arthralgia (infants, children, and adolescents: &lt;2%)
, gout (&lt;2%), lower extremity pain (&lt;2%), muscle spasm (&lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Renal: Fla
nk pain (&lt;2%), increased blood urea nitrogen (&lt;2%), increased serum c
reatinine (&lt;2%), renal insufficiency (&lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Respirator
y: Asthma (&lt;2%), bronchoconstriction (&lt;2%), cough (infants, children,
 adolescents, adults: E289A44%), dyspnea (1% to 3%), epistaxis (&lt;2%),
 hemoptysis (&lt;2%), hypoxemia (&lt;2%), nasopharyngitis (infants, childre
n, and adolescents: &lt;2%), pharyngitis (infants, children, adolescents, a
dults: &lt;2%; including viral), pleural effusion (infants, children, adole
scents, adults: &lt;2%), pleuritic chest pain (&lt;2%), rales (&lt;2%), res
piratory distress (&lt;2%), rhinitis (infants, children, and adolescents: &
lt;2%), rhinorrhea (infants, children, and adolescents: &lt;2%), rhonchi (&
lt;2%), upper respiratory tract infection (infants, children, and adolescen
ts: 2%), wheezing (infants, children, and adolescents: &lt;2%)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Miscellane
ous: Fever (infants, children, adolescents, adults: 2% to 5%), swelling (in
fants, children, adolescents, adults: E289A43%), tissue necrosis (&lt;2%
)</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">&lt;1%: Ne
rvous system: Seizure<span class3D"lexi-table-link-container"> (<a class
3D"lexi-table-link" data-table-id3D"lexi-content-seizure" aria-label3D"S
eizure table link">table 3</a>)</span><span 3D"display:none;" class
3D"table-link">Seizure</span></p>
                  <table border3D"1" data-table-id3D"Seizure" rules3D"al
l" id3D"lexi-content-seizure" data-hyperlink3D"yes" class3D"lexi-modal-c
ontent" frame3D"border">
                     <caption 3D"text-align:center;">
                        <b>Ertapenem: Adverse Reaction: Seizure</b></captio
n>
                     <colgroup><col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     <col align3D"left">
                     </colgroup><thead>
                        <tr>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Drug (Ertapenem)</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Comparator (Piperacillin and Tazobactam
)</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Comparator (Ceftriaxone)</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Population</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Dose</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Number of Patients (Ertapenem)</b></p><
/th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Number of Patients (Piperacillin and Ta
zobactam)</b></p></th>
                           <th align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>
                                 <b>Number of Patients (Ceftriaxone)</b></p
></th></tr></thead>
                     <tbody>
                        <tr>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>0.5%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>0.3%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>0%</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>Adults</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>1 g daily</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>1,954</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>774</p></td>
                           <td align3D"left">
                              <p 3D"text-indent:0em;text-align:left;"
>942</p></td></tr></tbody></table>
                  <p 3D"text-indent:-2em;margin-left:2em;">Postmarkin
g (any population):</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Dermatolog
ic: Acute generalized exanthematous pustulosis (Fernando 2013)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Endocrine 
&amp; metabolic: Hypoglycemia (Kennedy 2019)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Gastrointe
stinal: <i>Clostridioides difficile</i> colitis (Itani 2006), staining of t
ooth</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Hypersensi
tivity: Anaphylaxis, drug reaction with eosinophilia and systemic symptoms,
 hypersensitivity angiitis, nonimmune anaphylaxis</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Nervous sy
stem: Abnormal gait, ataxia, encephalopathy (Sutton 2017), hallucination (S
utton 2017), impaired consciousness, myasthenia, myoclonus</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Neuromuscu
lar &amp; skeletal: Dyskinesia</p></div>
<div id3D"F166515" class3D"block coi drugH1Div"><span class3D"drugH1">Co
ntraindications</span>
                  <p 3D"text-indent:0em;display:inline">Known hyperse
nsitivity to any component of this product or to other drugs in the same cl
ass or in patients who have demonstrated anaphylactic reactions to beta-lac
tams; known hypersensitivity to local anesthetics of the amide type due to 
the use of lidocaine as a diluent (IM use only).</p></div>
<div id3D"F166500" class3D"block war drugH1Div"><span class3D"drugH1">Wa
rnings/Precautions</span>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>
                        <i>Disease-related concerns:</i></b></p>
                  <p 3D"text-indent:-2em;margin-left:4em;">E280A2 
Renal impairment: Use with caution in patients with renal impairment; dosag
e adjustment required in patients with moderate to severe renal dysfunction
. Increased seizure risk has been reported in patients with renal dysfuncti
on.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>
                        <i>Concurrent drug therapy issues:</i></b></p>
                  <p 3D"text-indent:-2em;margin-left:4em;">E280A2 
Valproic acid and derivatives: Carbapenems, including ertapenem, may decrea
se the serum concentration of divalproex sodium/valproic acid increasing th
e risk of breakthrough seizures. Concurrent use of carbapenem antibiotics w
ith divalproex sodium/valproic acid is generally not recommended. Alternati
ve antimicrobial agents should be considered, but if a concurrent carbapene
m is necessary, consider additional antiseizure medication.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>
                        <i>Special populations:</i></b></p>
                  <p 3D"text-indent:-2em;margin-left:4em;">E280A2 
Older adult: Lower doses (based upon renal function) are often required in 
the elderly.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>
                        <i>Other warnings/precautions:</i></b></p>
                  <p 3D"text-indent:-2em;margin-left:4em;">E280A2 
IM administration: Doses for IM administration are mixed with lidocaine; co
nsult Lidocaine (Systemic) information for associated Warnings/Precautions.
</p></div>
<div id3D"F166510" class3D"block foc drugH1Div"><span class3D"drugH1">Do
sage Forms: US</span>
                  <p 3D"text-indent:0em;text-align:justify;display:in
line">Excipient information presented when available (limited, particularly
 for generics); consult specific product labeling.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;text-align:j
ustify;">Solution Reconstituted, Injection: </p>
                  <p 3D"text-indent:-2em;margin-left:4em;text-align:j
ustify;">Generic: 1 g (1 ea)</p>
                  <p 3D"text-indent:-2em;margin-left:2em;text-align:j
ustify;">Solution Reconstituted, Injection [preservative free]: </p>
                  <p 3D"text-indent:-2em;margin-left:4em;text-align:j
ustify;">INVanz: 1 g (1 ea)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;text-align:j
ustify;">Generic: 1 g (1 ea)</p></div>
<div id3D"F166496" class3D"block geq drugH1Div"><span class3D"drugH1">Ge
neric Equivalent Available: US</span>
                  <p 3D"text-indent:0em;display:inline">Yes</p></div>
<div id3D"F16323133" class3D"block fee drugH1Div"><span class3D"drugH1">
Pricing: US</span>
                  <p 3D"text-indent:-2em;margin-left:2em;text-align:j
ustify;">
                     <b>Solution (reconstituted)</b> (Ertapenem Sodium Inje
ction)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;text-align:j
ustify;">1 g (per each): $48.00 - $166.56</p>
                  <p 3D"text-indent:0em;">
                     <b>Disclaimer: </b>A representative AWP (Average Whole
sale Price) price or price range is provided as reference price only. A ran
ge is provided when more than one manufacturer's AWP price is available and
 uses the low and high price reported by the manufacturers to determine the
 range. The pricing data should be used for benchmarking purposes only, and
 as such should not be used alone to set or adjudicate any prices for reimb
ursement or purchasing functions or considered to be an exact price for a s
ingle product and/or manufacturer.  Medi-Span expressly disclaims all warra
nties of any kind or nature, whether express or implied, and assumes no lia
bility with respect to accuracy of price or price range data published in i
ts solutions.  In no event shall Medi-Span be liable for special, indirect,
 incidental, or consequential damages arising from use of price or price ra
nge data.  Pricing data is updated monthly.</p></div>
<div id3D"F52866778" class3D"block dinfoc drugH1Div"><span class3D"drugH
1">Dosage Forms: Canada</span>
                  <p 3D"text-indent:0em;text-align:justify;display:in
line">Excipient information presented when available (limited, particularly
 for generics); consult specific product labeling.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;text-align:j
ustify;">Solution Reconstituted, Injection: </p>
                  <p 3D"text-indent:-2em;margin-left:4em;text-align:j
ustify;">INVanz: 1 g (3.2 mL)</p>
                  <p 3D"text-indent:-2em;margin-left:4em;text-align:j
ustify;">Generic: 1 g (1 ea)</p></div>
<div id3D"F166512" class3D"block adm drugH1Div"><span class3D"drugH1">Ad
ministration: Adult</span>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>IM:</b> Avoid injection into a blood vessel. Make s
ure patient does not have an allergy to lidocaine or another anesthetic of 
the amide type. Administer by deep IM injection into a large muscle mass (e
g, gluteal muscle or lateral part of the thigh). Do not administer IM prepa
ration or drug reconstituted for IM administration intravenously.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>IV:</b> Administer as an IV infusion over 30 minute
s. May also administer IV push over 5 minutes (<span class3D"ref-callout-l
ist"><a class3D"ref-callout-list-link" lexi-content-ref-id3D"['lexi-conte
nt-ref-29992286','lexi-content-ref-23400916']" aria-label3D"list of refere
nces">Ref</a></span>).</p></div>
<div id3D"F52612718" class3D"block admp drugH1Div"><span class3D"drugH1"
>Administration: Pediatric</span>
                  <p 3D"text-indent:0em;display:inline">Parenteral:</
p>
                  <p 3D"text-indent:-2em;margin-left:2em;">IM: Admini
ster by deep IM injection into a large muscle mass such as the gluteus maxi
mus or lateral part of the thigh. Avoid injection into a blood vessel. Must
 be administered within 1 hour of reconstitution.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Intermitte
nt IV infusion: Infuse over 30 minutes; administration should be completed 
within 6 hours of reconstitution. Do not coinfuse with other medications. <
b>Do not infuse with dextrose-containing solutions.</b></p></div>
<div id3D"F166511" class3D"block use drugH1Div"><span class3D"drugH1">Us
e: Labeled Indications</span>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Intra-abdominal infection, mild to moderate, commun
ity-acquired in patients without risk factors for resistance or treatment f
ailure: </b>For the treatment of complicated intra-abdominal infections cau
sed by <i>Clostridium clostridioforme</i>, <i>Escherichia coli, </i>
                     <i>Eubacterium lentum</i>, <i>Peptostreptococcus</i> s
pp, <i>Bacteroides distasonis</i>, <i>Bacteroides fragilis</i>, <i>Bacteroi
des ovatus</i>, <i>Bacteroides thetaiotaomicron</i>, or <i>Bacteroides unif
ormis</i>.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Pelvic infection:</b> For the treatment of acute pe
lvic infections, including postpartum endomyometritis, septic abortion, and
 postsurgical gynecologic infections caused by <i>Streptococcus agalactiae<
/i>, <i>E. coli</i>, <i>B. fragilis</i>, <i>Porphyromonas asaccharolytica</
i>, <i>Peptostreptococcus</i> spp, or <i>Prevotella bivia</i>.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Pneumonia, community acquired:</b> For the treatmen
t of community-acquired pneumonia (CAP) caused by <i>Streptococcus pneumoni
ae</i> (penicillin-susceptible isolates only), including cases with concurr
ent bacteremia; <i>Haemophilus influenzae</i> (beta-lactamase-negative isol
ates only); or <i>Moraxella catarrhalis</i>.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Skin and skin structure infection, complicated:</b>
 For the treatment of complicated skin and skin structure infections, inclu
ding diabetic foot infections without osteomyelitis caused by <i>Staphyloco
ccus aureus</i> (methicillin-susceptible isolates only), <i>S. agalactiae</
i>, <i>Streptococcus pyogenes</i>, <i>E. coli</i>, <i>Klebsiella pneumoniae
</i>, <i>Proteus mirabilis</i>, <i>B. fragilis</i>, <i>Peptostreptococcus</
i> spp, <i>P. asaccharolytica</i>, or <i>P. bivia</i>. Ertapenem has not be
en studied in diabetic foot infections with concomitant osteomyelitis.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Surgical prophylaxis:</b> For the prophylaxis of su
rgical site infection in adults following elective colorectal surgery.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">
                     <b>Urinary tract infection, complicated (pyelonephriti
s or urinary tract infection with systemic signs/symptoms):</b> For the tre
atment of complicated urinary tract infection, including pyelonephritis cau
sed by <i>E. coli</i>, including cases with concurrent bacteremia or <i>K. 
pneumoniae</i>.</p>
                  <p 3D"text-indent:0em;margin-top:2em;">
                     <b>Note:</b> Methicillin-resistant <i>Staphylococcus a
ureus, Enterococcus</i> spp, <i>Acinetobacter</i>, <i>Pseudomonas aeruginos
a</i>, and penicillin-resistant strains of <i>Streptococcus pneumoniae </i>
are <b>resistant</b> to ertapenem while most extended-spectrum beta-lactama
se (ESBL)-producing bacteria remain sensitive to ertapenem.</p></div>
<div id3D"F25473714" class3D"block off-label drugH1Div"><span class3D"dr
ugH1">Use: Off-Label: Adult</span><p>Bite wound, treatment (animal or human
 bite); Bloodstream infection; Osteomyelitis and/or discitis; Pneumonia, ho
spital acquired or ventilator associated; Prosthetic joint infection</p></d
iv>
<div id3D"F166564" class3D"block mst drugH1Div"><span class3D"drugH1">Me
dication Safety Issues</span>
                  <div class3D"collapsible">
                     <span class3D"collapsible-title">Sound-alike/look-ali
ke issues:</span>
                     <div class3D"collapsible-wrap">
                        <p 3D"text-indent:-2em;margin-left:4em;">Erta
penem may be confused with doripenem, imipenem, meropenem</p>
                        <p 3D"text-indent:-2em;margin-left:4em;">Inva
nz may be confused with IV vancomycin</p></div>
</div>

                  <div class3D"collapsible">
                     <span class3D"collapsible-title">International issues
:</span>
                     <div class3D"collapsible-wrap">
                        <p 3D"text-indent:2em;">Invanz [US, Canada, Q
atar] may be confused with Avinza [Puerto Rico] and Evista brand name for r
aloxifene [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div id3D"F13299280" class3D"block cyt drugH1Div"><span class3D"drugH1">
Metabolism/Transport Effects</span>
                  <p 3D"text-indent:0em;display:inline">
                     <b>Substrate</b> of OAT1/3</p></div>
<div id3D"F166504" class3D"block dri drugH1Div"><span class3D"drugH1">Dr
ug Interactions</span><br><br><div class3D"clear"></div><p xmlns3D""></p>
<div xmlns3D"" class3D"inner"><p 3D"text-indent:0em;display:inline"
><b>Note</b>: Interacting drugs may <b>not be individually listed below</b>
 if they are part of a group interaction (eg, individual drugs within E2
809CCYP3A4 Inducers [Strong]E2809D are NOT listed).  For a complete li
st of drug interactions by individual drug name and detailed management rec
ommendations, use the Lexicomp drug interactions program by clicking on the
 E2809CLaunch drug interactions programE2809D link above.</p><p xmlns
3D""></p></div>

                  <p 3D"text-indent:-2em;margin-left:2em;">Bacillus c
lausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii
.  Management: Bacillus clausii should be taken in between antibiotic doses
 during concomitant therapy.<i> Risk D: Consider therapy modification</i></
p>
                  <p 3D"text-indent:-2em;margin-left:2em;">BCG (Intra
vesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesi
cal). <i> Risk X: Avoid combination</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">BCG Vaccin
e (Immunization): Antibiotics may diminish the therapeutic effect of BCG Va
ccine (Immunization). <i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Cholera Va
ccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. 
 Management: Avoid cholera vaccine in patients receiving systemic antibioti
cs, and within 14 days following the use of oral or parenteral antibiotics.
<i> Risk X: Avoid combination</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Fecal Micr
obiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i
> Risk X: Avoid combination</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Fecal Micr
obiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of 
Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Fexinidazo
le: May increase the serum concentration of OAT1/3 Substrates (Clinically R
elevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when
 possible. If combined, monitor for increased OAT1/3 substrate toxicities.<
i> Risk D: Consider therapy modification</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Immune Che
ckpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics m
ay diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD
-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Lactobacil
lus and Estriol: Antibiotics may diminish the therapeutic effect of Lactoba
cillus and Estriol. <i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Leflunomid
e: May increase the serum concentration of OAT1/3 Substrates (Clinically Re
levant).<i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Nitisinone
: May increase the serum concentration of OAT1/3 Substrates (Clinically Rel
evant).<i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Pretomanid
: May increase the serum concentration of OAT1/3 Substrates (Clinically Rel
evant).<i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Probenecid
: May increase the serum concentration of Ertapenem.<i> Risk X: Avoid combi
nation</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Sodium Pic
osulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosul
fate.  Management: Consider using an alternative product for bowel cleansin
g prior to a colonoscopy in patients who have recently used or are concurre
ntly using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Tacrolimus
 (Systemic): Ertapenem may increase the serum concentration of Tacrolimus (
Systemic). <i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Taurursodi
ol: May increase the serum concentration of OAT1/3 Substrates (Clinically R
elevant).<i> Risk X: Avoid combination</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Teriflunom
ide: May increase the serum concentration of OAT1/3 Substrates (Clinically 
Relevant).<i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Typhoid Va
ccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. 
Only the live attenuated Ty21a strain is affected.  Management: Avoid use o
f live attenuated typhoid vaccine (Ty21a)  in patients being treated with s
ystemic antibacterial agents. Postpone vaccination until 3 days after cessa
tion of antibiotics and avoid starting antibiotics within 3 days of last va
ccine dose.<i> Risk D: Consider therapy modification</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Vaborbacta
m: May increase the serum concentration of OAT1/3 Substrates (Clinically Re
levant).<i> Risk C: Monitor therapy</i></p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Valproate 
Products: Carbapenems may decrease the serum concentration of Valproate Pro
ducts.  Management: Concurrent use of carbapenem antibiotics with valproic 
acid is generally not recommended.  Alternative antimicrobial agents should
 be considered, but if a concurrent carbapenem is necessary, consider addit
ional anti-seizure medication.<i> Risk D: Consider therapy modification</i>
</p></div>
<div id3D"F166516" class3D"block pri drugH1Div"><span class3D"drugH1">Pr
egnancy Considerations</span>
                  <p 3D"text-indent:0em;display:inline">Ertapenem is 
approved for the treatment of postpartum endomyometritis, septic abortion, 
and postsurgical infections. Ertapenem may be considered for use as an alte
rnative antibiotic in the treatment of intraamniotic infection (ACOG 712 20
17).</p></div>
<div id3D"F166517" class3D"block brc drugH1Div"><span class3D"drugH1">Br
eastfeeding Considerations</span>
                  <p 3D"text-indent:-2em;margin-left:2em;">Ertapenem 
is present in breast milk.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">The relati
ve infant dose (RID) of ertapenem is &lt;1% when calculated using the highe
st breast milk concentration located and compared to a weight-adjusted mate
rnal dose of 1 g/day.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">In general
, breastfeeding is considered acceptable when the RID of a medication is &l
t;10% (Anderson 2016; Ito 2000).</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">The RID of
 ertapenem was calculated using a milk concentration of 0.38 mcg/mL, provid
ing an estimated daily infant dose via breast milk of 57 mcg/kg/day. This m
ilk concentration was obtained following maternal administration ertapenem 
1 g IV to five lactating women at 5 to14 days postpartum. Milk concentratio
ns were measured randomly for 5 days following the last dose. The milk conc
entration within 24 hours of the last dose ranged from &lt;0.13 mcg/mL (low
er limit of quantitation) to 0.38 mcg/mL. Peak concentrations were not asse
ssed. Ertapenem was not detectable in the milk of four women and was less t
han the lower limit of quantitation in one woman by day 5 after the last do
se.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">According 
to the manufacturer, the decision to breastfeed during therapy should consi
der the risk of infant exposure, the benefits of breastfeeding to the infan
t, and benefits of treatment to the mother. In general, antibiotics that ar
e present in breast milk may cause non-dose-related modification of bowel f
lora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 
2002).</p></div>
<div id3D"F166518" class3D"block dic drugH1Div"><span class3D"drugH1">Di
etary Considerations</span>
                  <p 3D"text-indent:0em;display:inline">Some products
 may contain sodium.</p></div>
<div id3D"F166508" class3D"block mop drugH1Div"><span class3D"drugH1">Mo
nitoring Parameters</span>
                  <p 3D"text-indent:0em;display:inline">Periodic rena
l, hepatic, and hematopoietic assessment during prolonged therapy; neurolog
ical assessment</p></div>
<div id3D"F166499" class3D"block pha drugH1Div"><span class3D"drugH1">Me
chanism of Action</span>
                  <p 3D"text-indent:0em;display:inline">Inhibits bact
erial cell wall synthesis by binding to one or more of the penicillin-bindi
ng proteins; which in turn inhibits the final transpeptidation step of pept
idoglycan synthesis in bacterial cell walls, thus inhibiting cell wall bios
ynthesis. Bacteria eventually lyse due to ongoing activity of cell wall aut
olytic enzymes (autolysins and murein hydrolases) while cell wall assembly 
is arrested.</p></div>
<div id3D"F166514" class3D"block phk drugH1Div"><span class3D"drugH1">Ph
armacokinetics (Adult Data Unless Noted)</span>
                  <p 3D"text-indent:-2em;margin-left:2em;">Absorption
: IM: Almost complete</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Distributi
on: V<sub>dss</sub>:</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Infants 
E289A53 months and Children: ~0.2 L/kg</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Adolescent
s 13 to 17 years: ~0.16 L/kg</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Adults: ~0
.12 L/kg</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Protein bi
nding (concentration dependent, primarily to albumin): 85% at 300 mcg/mL, 9
5% at &lt;100 mcg/mL</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Metabolism
: Non-CYP-mediated hydrolysis to inactive metabolite</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Bioavailab
ility: IM: ~90%</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Half-life 
elimination:</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Infants 
E289A53 months and Children: ~2.5 hours</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">Adolescent
s and Adults: ~4 hours</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Time to pe
ak: IM: ~2.3 hours</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Excretion:
 Urine (~80% as unchanged drug and metabolite); feces (~10%)</p></div>
<div id3D"F51154053" class3D"block phksp drugH1Div"><span class3D"drugH1
">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</sp
an>
                  <p 3D"text-indent:-2em;margin-left:2em;">Altered ki
dney function: Unbound AUC increased 1.5- and 2.3-fold in those with mild a
nd moderate renal function impairment, respectively. Unbound AUC increased 
4.4- and 7.6-fold in those with advanced renal impairment and end-stage ren
al disease, respectively.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Older adul
t: The total and unbound AUC increased 37% and 67%, respectively, in elderl
y patients relative to younger patients.</p>
                  <p 3D"text-indent:-2em;margin-left:2em;">Anti-infec
tive considerations:</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <i>Parameters associated with efficacy:</i></p>
                  <p 3D"text-indent:-2em;margin-left:6em;">Time depen
dent; associated with time free drug concentration (<i>f</i>T) &gt; minimum
 inhibitory concentration (MIC).</p>
                  <p 3D"text-indent:-2em;margin-left:8em;">Organism s
pecific:</p>
                  <p 3D"text-indent:-2em;margin-left:10em;">Gram-nega
tive organisms (<i>E. coli</i>, <i>K. pneumoniae</i>): Goal: E289A540% <
i>f</i>T &gt; MIC (bactericidal) (DeRyke 2011).</p>
                  <p 3D"text-indent:-2em;margin-left:10em;">
                     <i>S. pneumoniae</i>: Goal: E289A530% <i>f</i>T &gt
; MIC (bactericidal) (Xuan 2002).</p>
                  <p 3D"text-indent:-2em;margin-left:8em;">Population
 specific:</p>
                  <p 3D"text-indent:-2em;margin-left:10em;">Criticall
y ill patients in the ICU: Minimum goal: E289A550% <i>f</i>T &gt; MIC; p
referred goal: E289A5100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 
2020; Roberts 2014); some experts favor E289A5100% <i>f</i>T &gt; 4 time
s the MIC (Guilhaumou 2019).</p>
                  <p 3D"text-indent:-2em;margin-left:6em;">Expected d
rug exposure in normal renal function:</p>
                  <p 3D"text-indent:-2em;margin-left:8em;">C<sub>max 
</sub>(peak): Single dose:</p>
                  <p 3D"text-indent:-2em;margin-left:10em;">Infants a
nd children 3 to 23 months of age: IV: 15 mg/kg (maximum dose: 1 g): 103.8 
mg/L.</p>
                  <p 3D"text-indent:-2em;margin-left:10em;">Children 
2 to 12 years of age: IV: 15 mg/kg (maximum dose: 1 g): 113.2 mg/L.</p>
                  <p 3D"text-indent:-2em;margin-left:10em;">Adolescen
ts 13 to 17 years of age: IV: 1 g: 155.9 mg/L.</p>
                  <p 3D"text-indent:-2em;margin-left:10em;">Adults:</
p>
                  <p 3D"text-indent:-2em;margin-left:12em;">IV: 1 g: 
155 mg/L.</p>
                  <p 3D"text-indent:-2em;margin-left:12em;">IM: 1 g: 
67 mg/L.</p>
                  <p 3D"text-indent:-2em;margin-left:4em;">
                     <i>Postantibiotic effect: </i>Minimal bacterial killin
g continues after ertapenem concentration falls below the MIC of targeted p
athogen and varies based on the organism:</p>
                  <p 3D"text-indent:-2em;margin-left:6em;">
                     <i>S. aureus</i>: ~1.5 hours (Odenholt 1998).</p>
                  <p 3D"text-indent:-2em;margin-left:6em;">
                     <i>S. pneumoniae</i>: ~2.4 hours (Odenholt 1998).</p>
                  <p 3D"text-indent:-2em;margin-left:6em;">Gram-negat
ive organisms (<i>Enterobacter cloacae</i>, <i>E. coli</i>, <i>H. influenza
e</i>): E289A40.7 hours (Odenholt 1998).</p></div>
<div id3D"F2869380" class3D"list fbnlist drugH1Div drugBrandNames"><span 
class3D"drugH1">Brand Names: International</span><div class3D"ibn-search 
drugBrandNames"></div>
<div class3D"collapsible-indication brand-names-accordion drugBrandNames">
<span class3D"collapsible-indication-title">International Brand Names by C
ountry</span><div class3D"collapsible-indication-wrap-frame drugBrandNames
"><div class3D"collapsible-indication-wrap drugBrandNames">For country cod
e abbreviations (<a class3D"graphic graphic_table" rel3D"external" href
3D"/d/html/116421">show table</a>)<br xmlns3D"">
<br><ul>
                     <li>
                        <span class3D"countryCode">(BD)</span> <span class
3D"country">Bangladesh</span><span class3D"countrySeparator">: </span><sp
an class3D"drugName">Wandara</span>;</li>
                     <li>
                        <span class3D"countryCode">(ET)</span> <span class
3D"country">Ethiopia</span><span class3D"countrySeparator">: </span><span
 class3D"drugName">Ertapenem</span>;</li>
                     <li>
                        <span class3D"countryCode">(IN)</span> <span class
3D"country">India</span><span class3D"countrySeparator">: </span><span cl
ass3D"drugName">Ertiga</span>;</li>
                     <li>
                        <span class3D"countryCode">(PY)</span> <span class
3D"country">Paraguay</span><span class3D"countrySeparator">: </span><span
 class3D"drugName">Ertapenem bergamo | Ertapenem imedic</span>;</li>
                     <li>
                        <span class3D"countryCode">(QA)</span> <span class
3D"country">Qatar</span><span class3D"countrySeparator">: </span><span cl
ass3D"drugName">Invanz</span>;</li>
                     <li>
                        <span class3D"countryCode">(ZA)</span> <span class
3D"country">South Africa</span><span class3D"countrySeparator">: </span><
span class3D"drugName">Iverzam</span></li></ul></div>
</div>
</div>
</div>
</div><div id3D"references" class3D"headingAnchor"><ol id3D"reference">
<li>
<div class3D"reference" id3D"lexi-content-ref-32383061">
                 20
                     <a name3D"32383061"></a>Abdul-Aziz MH, Alffenaar JC, 
Bassetti M, et al; Infection Section of European Society of Intensive Care 
Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patien
t study groups of European Society of Clinical Microbiology and Infectious 
Diseases (ESCMID); Infectious Diseases Group of International Association o
f Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections
 in the ICU and sepsis working group of International Society of Antimicrob
ial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in criti
cally ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020
;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class3D"pubmed-id"> 
[PubMed <a id3D"32383061" target3D"_blank" href3D"https://www.uptodate.c
om/contents/ertapenem-drug-information/abstract-text/32383061/pubmed">32383
061</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-32910809">
                 20
                     <a name3D"32910809"></a>Al-Shaer MH, Rubido E, Cherab
uddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring 
of CEB2-lactams and associated therapy outcomes in critically ill patient
s. <i>J Antimicrob Chemother.</i> 2020;75(12):3644-3651. doi:10.1093/jac/dk
aa359<span class3D"pubmed-id"> [PubMed <a id3D"32910809" target3D"_blank
" href3D"https://www.uptodate.com/contents/ertapenem-drug-information/abst
ract-text/32910809/pubmed">32910809</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-AAP.1">
                 20
                     <a name3D"AAP.1"></a>American Academy of Pediatrics (
AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 20
18 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL:
 American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-28742677">
                 20
                     <a name3D"28742677"></a>American College of Obstetric
ians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee op
inion no. 712: intrapartum management of intraamniotic infection. <i>Obstet
 Gynecol</i>. 2017;130(2):e95-e101.<span class3D"pubmed-id"> [PubMed <a id
3D"28742677" target3D"_blank" href3D"https://www.uptodate.com/contents/e
rtapenem-drug-information/abstract-text/28742677/pubmed">28742677</a>]</spa
n>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Anderson.1">
                 20
                     <a name3D"Anderson.1"></a>Anderson DJ, Sexton DJ. Ant
imicrobial prophylaxis for prevention of surgical site infection in adults.
 Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a target3D"_blank" hre
f3D"http://www.uptodate.com/">http://www.uptodate.com</a>. Accessed May 29
, 2019.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-27060684">
                 20
                     <a name3D"27060684"></a>Anderson PO, Sauberan JB. Mod
eling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1)
:42-52.<span class3D"pubmed-id"> [PubMed <a id3D"27060684" target3D"_bla
nk" href3D"https://www.uptodate.com/contents/ertapenem-drug-information/ab
stract-text/27060684/pubmed">27060684</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-18945594">
                 20
                     <a name3D"18945594"></a>Arguedas A, Cespedes J, Botet
 FA, et al. Safety and tolerability of ertapenem versus ceftriaxone in a do
uble-blind study performed in children with complicated urinary tract infec
tion, community-acquired pneumonia or skin and soft-tissue infection. <i>In
t J Antimicrob Agents</i>. 2009;33(2):163-167.<span class3D"pubmed-id"> [P
ubMed <a id3D"18945594" target3D"_blank" href3D"https://www.uptodate.com
/contents/ertapenem-drug-information/abstract-text/18945594/pubmed">1894559
4</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Baddour.1">
                 20
                     <a name3D"Baddour.1"></a>Baddour LM. Soft tissue infe
ctions due to dog and cat bites. Post TW, ed. UpToDate. Waltham, MA: UpToDa
te Inc. <a target3D"_blank" href3D"http://www.uptodate.com/">http://www.u
ptodate.com</a>. Accessed February 25, 2019a.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Baddour.2">
                 20
                     <a name3D"Baddour.2"></a>Baddour LM. Soft tissue infe
ctions due to human bites. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc
. <a target3D"_blank" href3D"http://www.uptodate.com/">http://www.uptodat
e.com</a>. Accessed February 25, 2019b.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Barshak.1">
                 20
                     <a name3D"Barshak.1"></a>Barshak MB. Antimicrobial ap
proach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Walt
ham, MA: UpToDate Inc. <a target3D"_blank" href3D"http://www.uptodate.com
/">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Expert.1">
                 20
                     <a name3D"Expert.1"></a>Based on expert opinion.</div
>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-17540673">
                 20
                     <a name3D"17540673"></a>Bassetti M, Righi E, Fasce R,
 et al. Efficacy of ertapenem in the treatment of early ventilator-associat
ed pneumonia caused by extended-spectrum beta-lactamase-producing organisms
 in an intensive care unit. <i>J Antimicrob Chemother</i>. 2007;60(2):433-4
35. doi: 10.1093/jac/dkm180.<span class3D"pubmed-id"> [PubMed <a id3D"175
40673" target3D"_blank" href3D"https://www.uptodate.com/contents/ertapene
m-drug-information/abstract-text/17540673/pubmed">17540673</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-26229122">
                 20
                     <a name3D"26229122"></a>Berbari EF, Kanj SS, Kowalski
 TJ, et al; Infectious Diseases Society of America. 2015 Infectious Disease
s Society of America (IDSA) clinical practice guidelines for the diagnosis 
and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect D
is</i>. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482.<span class3D"pubmed-i
d"> [PubMed <a id3D"26229122" target3D"_blank" href3D"https://www.uptoda
te.com/contents/ertapenem-drug-information/abstract-text/26229122/pubmed">2
6229122</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-28467526">
                 20
                     <a name3D"28467526"></a>BerrC3ADos-Torres SI, Umsch
eid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory
 Committee. Centers for Disease Control and Prevention guideline for the pr
evention of surgical site infection, 2017 [published correction appears in 
<i>JAMA Surg</i>. 2017;152(8):803]. <i>JAMA Surg</i>. 2017;152(8):784-791. 
doi: 10.1001/jamasurg.2017.0904.<span class3D"pubmed-id"> [PubMed <a id3D
"28467526" target3D"_blank" href3D"https://www.uptodate.com/contents/erta
penem-drug-information/abstract-text/28467526/pubmed">28467526</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-30558872">
                 20
                     <a name3D"30558872"></a>Blumenthal KG, Peter JG, Trub
iano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):18
3-198. doi:10.1016/S0140-6736(18)32218-9<span class3D"pubmed-id"> [PubMed 
<a id3D"30558872" target3D"_blank" href3D"https://www.uptodate.com/conte
nts/ertapenem-drug-information/abstract-text/30558872/pubmed">30558872</a>]
</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-21880587">
                 20
                     <a name3D"21880587"></a>Bradley JS, Byington CL, Shah
 SS, et al. The management of community-acquired pneumonia in infants and c
hildren older than 3 months of age: clinical practice guidelines by the Ped
iatric Infectious Diseases Society and the Infectious Diseases Society of A
merica. <i>Clin Infect Dis</i>. 2011;53(7):e25-76.<span class3D"pubmed-id"
> [PubMed <a id3D"21880587" target3D"_blank" href3D"https://www.uptodate
.com/contents/ertapenem-drug-information/abstract-text/21880587/pubmed">218
80587</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Bradley.1">
                 20
                     <a name3D"Bradley.1"></a>Bradley JS and Nelson JD, ed
s. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: Am
erican Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-23327981">
                 20
                     <a name3D"23327981"></a>Bratzler DW, Dellinger EP, Ol
sen KM, et al; American Society of Health-System Pharmacists; Infectious Di
sease Society of America; Surgical Infection Society; Society for Healthcar
e Epidemiology of America. Clinical practice guidelines for antimicrobial p
rophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283. d
oi: 10.2146/ajhp120568.<span class3D"pubmed-id"> [PubMed <a id3D"23327981
" target3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-dru
g-information/abstract-text/23327981/pubmed">23327981</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-26120552">
                 20
                     <a name3D"26120552"></a>Brockow K, Przybilla B, Abere
r W, et al. Guideline for the diagnosis of drug hypersensitivity reactions:
 S2K-Guideline of the German Society for Allergology and Clinical Immunolog
y (DGAKI) and the German Dermatological Society (DDG) in collaboration with
 the Association of German Allergologists (AeDA), the German Society for Pe
diatric Allergology and Environmental Medicine (GPA), the German Contact De
rmatitis Research Group (DKG), the Swiss Society for Allergy and Immunology
 (SGAI), the Austrian Society for Allergology and Immunology (C396GAI), t
he German Academy of Allergology and Environmental Medicine (DAAU), the Ger
man Center for Documentation of Severe Skin Reactions and the German Federa
l Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2
015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class3D"pubmed-id"> [
PubMed <a id3D"26120552" target3D"_blank" href3D"https://www.uptodate.co
m/contents/ertapenem-drug-information/abstract-text/26120552/pubmed">261205
52</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-27164625">
                 20
                     <a name3D"27164625"></a>Buonomo A, Pascolini L, Rizzi
 A, et al. Cross-reactivity and tolerability of ertapenem in patients with 
IgE-mediated hypersensitivity to CEB2-lactams. <i>J Investig Allergol Cli
n Immunol</i>. 2016;26(2):100-105. doi:10.18176/jiaci.0019<span class3D"pu
bmed-id"> [PubMed <a id3D"27164625" target3D"_blank" href3D"https://www.
uptodate.com/contents/ertapenem-drug-information/abstract-text/27164625/pub
med">27164625</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-18723863">
                 20
                     <a name3D"18723863"></a>Burkhardt O, Hafer C, Langhof
f A, et al. Pharmacokinetics of ertapenem in critically ill patients with a
cute renal failure undergoing extended daily dialysis. <i>Nephrol Dial Tran
splant</i>. 2009;24(1):267-271. doi: 10.1093/ndt/gfn472.<span class3D"pubm
ed-id"> [PubMed <a id3D"18723863" target3D"_blank" href3D"https://www.up
todate.com/contents/ertapenem-drug-information/abstract-text/18723863/pubme
d">18723863</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-22083473">
                 20
                     <a name3D"22083473"></a>Cardone KE, Grabe DW, Kulawy 
RW, et al. Ertapenem pharmacokinetics and pharmacodynamics during continuou
s ambulatory peritoneal dialysis.<i> Antimicrob Agents Chemother</i>. 2012;
56(2):725-730.<span class3D"pubmed-id"> [PubMed <a id3D"22083473" target
3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-drug-inform
ation/abstract-text/22083473/pubmed">22083473</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-24755188">
                 20
                     <a name3D"24755188"></a>Collins CE, Ayturk MD, Flahiv
e JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of co
mmunity-acquired <i>Clostridium difficile</i> infections in Medicare benefi
ciaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jam
collsurg.2014.01.053<span class3D"pubmed-id"> [PubMed <a id3D"24755188" t
arget3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-drug-i
nformation/abstract-text/24755188/pubmed">24755188</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-22290982">
                 20
                     <a name3D"22290982"></a>Collins VL, Marchaim D, Pogue
 JM, et al. Efficacy of ertapenem for treatment of bloodstream infections c
aused by extended-spectrum-CEB2-lactamase-producing Enterobacteriaceae. <
i>Antimicrob Agents Chemother</i>. 2012;56(4):2173-2177. doi: 10.1128/AAC.0
5913-11.<span class3D"pubmed-id"> [PubMed <a id3D"22290982" target3D"_bl
ank" href3D"https://www.uptodate.com/contents/ertapenem-drug-information/a
bstract-text/22290982/pubmed">22290982</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-29689301">
                 20
                     <a name3D"29689301"></a>Connelly S, Subramanian P, Ha
san NA, Colwell RR, Kaleko M. Distinct consequences of amoxicillin and erta
penem exposure in the porcine gut microbiome. <i>Anaerobe</i>. 2018;53:82-9
3. doi:10.1016/j.anaerobe.2018.04.012<span class3D"pubmed-id"> [PubMed <a 
id3D"29689301" target3D"_blank" href3D"https://www.uptodate.com/contents
/ertapenem-drug-information/abstract-text/29689301/pubmed">29689301</a>]</s
pan>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-12921489">
                 20
                     <a name3D"12921489"></a>Curran M, Simpson D, Perry C.
 Ertapenem: A Review of Its Use in the Management of Bacterial Infections. 
<i>Drugs.</i> 2003;63(17):1855-1878.<span class3D"pubmed-id"> [PubMed <a i
d3D"12921489" target3D"_blank" href3D"https://www.uptodate.com/contents/
ertapenem-drug-information/abstract-text/12921489/pubmed">12921489</a>]</sp
an>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-36669519">
                 20
                     <a name3D"36669519"></a>de Wijkerslooth EML, Boerma E
G, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postope
rative antibiotics for complex appendicitis: a pragmatic, open-label, multi
centre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):36
6-376. doi:10.1016/S0140-6736(22)02588-0<span class3D"pubmed-id"> [PubMed 
<a id3D"36669519" target3D"_blank" href3D"https://www.uptodate.com/conte
nts/ertapenem-drug-information/abstract-text/36669519/pubmed">36669519</a>]
</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-17283197">
                 20
                     <a name3D"17283197"></a>DeRyke CA, Banevicius MA, Fan
 HW, Nicolau DP. Bactericidal activities of meropenem and ertapenem against
 extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella
 pneumoniae in a neutropenic mouse thigh model. <i>Antimicrob Agents Chemot
her</i>. 2007;51(4):1481-1486. doi:10.1128/AAC.00752-06<span class3D"pubme
d-id"> [PubMed <a id3D"17283197" target3D"_blank" href3D"https://www.upt
odate.com/contents/ertapenem-drug-information/abstract-text/17283197/pubmed
">17283197</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-21177419">
                 20
                     <a name3D"21177419"></a>Duquaine S, Kitchell E, Tate 
T, Tannen RC, Wickremasinghe IM. Central nervous system toxicity associated
 with ertapenem use. <i>Ann Pharmacother</i>. 2011;45(1):e6. doi:10.1345/ap
h.1P528<span class3D"pubmed-id"> [PubMed <a id3D"21177419" target3D"_bla
nk" href3D"https://www.uptodate.com/contents/ertapenem-drug-information/ab
stract-text/21177419/pubmed">21177419</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-32618479">
                 20
                     <a name3D"32618479"></a>El Nekidy WS, Elrefaei H, St 
John TJL, et al. Ertapenem neurotoxicity in hemodialysis patients-safe and 
effective dosing is still needed: a retrospective study and literature revi
ew. <i>Ann Pharmacother</i>. 2021;55(1):52-58. doi:10.1177/1060028020938059
<span class3D"pubmed-id"> [PubMed <a id3D"32618479" target3D"_blank" hre
f3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-
text/32618479/pubmed">32618479</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-24323468">
                 20
                     <a name3D"24323468"></a>Eyler RF, Vilay AM, Nader AM,
 et al. Pharmacokinetics of ertapenem in critically ill patients receiving 
continuous venovenous hemodialysis or hemodiafiltration. <i>Antimicrob Agen
ts Chemother</i>. 2014;58(3):1320-1326. doi: 10.1128/AAC.02090-12.<span cla
ss3D"pubmed-id"> [PubMed <a id3D"24323468" target3D"_blank" href3D"http
s://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/2432
3468/pubmed">24323468</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-CDC.1">
                 20
                     <a name3D"CDC.1"></a>FAQs for clinicians about <i>C. 
diff</i>. Centers for Disease Control and Prevention. Updated October 25, 2
022. Accessed July 19, 2023. <a target3D"_blank" href3D"https://www.cdc.g
ov/cdiff/clinicians/faq.html">https://www.cdc.gov/cdiff/clinicians/faq.html
</a>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-23886234">
                 20
                     <a name3D"23886234"></a>Fernando SL. Ertapenem-induce
d acute generalized exanthematous pustulosis with cross-reactivity to other
 beta-lactam antibiotics on patch testing. <i>Ann Allergy Asthma Immunol</i
>. 2013;111(2):139-140. doi:10.1016/j.anai.2013.05.015<span class3D"pubmed
-id"> [PubMed <a id3D"23886234" target3D"_blank" href3D"https://www.upto
date.com/contents/ertapenem-drug-information/abstract-text/23886234/pubmed"
>23886234</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-File.1">
                 20
                     <a name3D"File.1"></a>File TM. Treatment of community
-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpT
oDate. Waltham, MA: UpToDate Inc. <a target3D"_blank" href3D"http://www.u
ptodate.com/">http://www.uptodate.com</a>. Accessed September 28, 2021.</di
v>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-25457154">
                 20
                     <a name3D"25457154"></a>Gaeta F, Valluzzi RL, Alonzi 
C, Maggioletti M, Caruso C, Romano A. Tolerability of aztreonam and carbape
nems in patients with IgE-mediated hypersensitivity to penicillins. <i>J Al
lergy Clin Immunol</i>. 2015;135(4):972-976. doi:10.1016/j.jaci.2014.10.011
<span class3D"pubmed-id"> [PubMed <a id3D"25457154" target3D"_blank" hre
f3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-
text/25457154/pubmed">25457154</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-24060141">
                 20
                     <a name3D"24060141"></a>Geerlings CJ, de Man P, Rietv
eld AP, Touw DJ, Cohen Tervaert JW. A practical thrice weekly ertapenem dos
age regime for chronic hemodialysis patients? <i>Clin Nephrol</i>. 2013;80(
4):312. doi: 10.5414/cn108071.<span class3D"pubmed-id"> [PubMed <a id3D"2
4060141" target3D"_blank" href3D"https://www.uptodate.com/contents/ertape
nem-drug-information/abstract-text/24060141/pubmed">24060141</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-36740326">
                 20
                     <a name3D"36740326"></a>Gibson A, Deshpande P, Campbe
ll CN, et al. Updates on the immunopathology and genomics of severe cutaneo
us adverse drug reactions. <i>J Allergy Clin Immunol</i>. 2023;151(2):289-3
00.e4. doi:10.1016/j.jaci.2022.12.005<span class3D"pubmed-id"> [PubMed <a 
id3D"36740326" target3D"_blank" href3D"https://www.uptodate.com/contents
/ertapenem-drug-information/abstract-text/36740326/pubmed">36740326</a>]</s
pan>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-30763732">
                 20
                     <a name3D"30763732"></a>Gil-Serrano J, Cardona V, Lue
ngo O, et al. Anaphylactic shock to meropenem with ertapenem tolerance: a c
ase report. <i>J Allergy Clin Immunol Pract</i>. 2019;7(6):2057-2058. doi:1
0.1016/j.jaip.2019.01.052<span class3D"pubmed-id"> [PubMed <a id3D"307637
32" target3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-d
rug-information/abstract-text/30763732/pubmed">30763732</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-29090866">
                 20
                     <a name3D"29090866"></a>Gomi H, Solomkin JS, Schlossb
erg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholan
gitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci</i>. 2018;25(1):3-
16. doi: 10.1002/jhbp.518.<span class3D"pubmed-id"> [PubMed <a id3D"29090
866" target3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-
drug-information/abstract-text/29090866/pubmed">29090866</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-22047594">
                 20
                     <a name3D"22047594"></a>Goswami ND, Johnson MD, Chu V
H. Ertapenem for treatment of osteomyelitis: a case series.<i> BMC Res Note
s</i>. 2011;4:478. doi: 10.1186/1756-0500-4-478.<span class3D"pubmed-id"> 
[PubMed <a id3D"22047594" target3D"_blank" href3D"https://www.uptodate.c
om/contents/ertapenem-drug-information/abstract-text/22047594/pubmed">22047
594</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-30925922">
                 20
                     <a name3D"30925922"></a>Guilhaumou R, Benaboud S, Ben
nis Y, et al. Optimization of the treatment with beta-lactam antibiotics in
 critically ill patients-guidelines from the French Society of Pharmacology
 and Therapeutics (SociC3A9tC3A9 FranC3A7aise de Pharmacologie et Th
C3A9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive 
Care Medicine (SociC3A9tC3A9 FranC3A7aise d'AnesthC3A9sie et RC3
A9animation-SFAR). <i>Crit Care.</i> 2019;23(1):104. doi:10.1186/s13054-01
9-2378-9<span class3D"pubmed-id"> [PubMed <a id3D"30925922" target3D"_bl
ank" href3D"https://www.uptodate.com/contents/ertapenem-drug-information/a
bstract-text/30925922/pubmed">30925922</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Hooton.1">
                 20
                     <a name3D"Hooton.1"></a>Gupta K. Acute complicated ur
inary tract infection (including pyelonephritis) in adults. Post TW, ed. Up
ToDate. Waltham, MA: UpToDate Inc. <a target3D"_blank" href3D"http://www.
uptodate.com/">http://www.uptodate.com</a>. Accessed March 20, 2021.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-21292654">
                 20
                     <a name3D"21292654"></a>Gupta K, Hooton TM, Naber KG,
 et al. International clinical practice guidelines for the treatment of acu
te uncomplicated cystitis and pyelonephritis in women: a 2010 update by the
 Infectious Diseases Society of America and the European Society for Microb
iology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e12
0.<span class3D"pubmed-id"> [PubMed <a id3D"21292654" target3D"_blank" h
ref3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstrac
t-text/21292654/pubmed">21292654</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-26907184">
                 20
                     <a name3D"26907184"></a>GutiC3A9rrez-GutiC3A9rrez
 B, Bonomo RA, Carmeli Y, et al; REIPI/ESGBIS/INCREMENT Group. Ertapenem fo
r the treatment of bloodstream infections due to ESBL-producing Enterobacte
riaceae: a multinational pre-registered cohort study. <i>J Antimicrob Chemo
ther</i>. 2016;71(6):1672-1680. doi: 10.1093/jac/dkv502.<span class3D"pubm
ed-id"> [PubMed <a id3D"26907184" target3D"_blank" href3D"https://www.up
todate.com/contents/ertapenem-drug-information/abstract-text/26907184/pubme
d">26907184</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-23871314">
                 20
                     <a name3D"23871314"></a>Hansen D, Pollan LD, Fernando
 H. Fulminant <i>Clostridium difficile</i> colitis: a complication of perio
perative antibiotic prophylaxis. <i>J Oral Maxillofac Surg</i>. 2013;71(11)
:1880-1885. doi:10.1016/j.joms.2013.04.035<span class3D"pubmed-id"> [PubMe
d <a id3D"23871314" target3D"_blank" href3D"https://www.uptodate.com/con
tents/ertapenem-drug-information/abstract-text/23871314/pubmed">23871314</a
>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-22146873">
                 20
                     <a name3D"22146873"></a>Hensgens MP, Goorhuis A, Dekk
ers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium diff
icile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemothe
r</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class3D"pubmed-id">
 [PubMed <a id3D"22146873" target3D"_blank" href3D"https://www.uptodate.
com/contents/ertapenem-drug-information/abstract-text/22146873/pubmed">2214
6873</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-8383938">
                 20
                     <a name3D"8383938"></a>Hikida M, Masukawa Y, Nishiki 
K, Inomata N. Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbap
enem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, an
d glycine receptor binding in relation to lack of central nervous system to
xicity in rats. <i>Antimicrob Agents Chemother</i>. 1993;37(2):199-202. doi
:10.1128/AAC.37.2.199<span class3D"pubmed-id"> [PubMed <a id3D"8383938" t
arget3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-drug-i
nformation/abstract-text/8383938/pubmed">8383938</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-29992286">
                 20
                     <a name3D"29992286"></a>Hsaiky LM, Salinitri FD, Wong
 J, et al. Pharmacokinetics and investigation of optimal dose ertapenem in 
intermittent hemodialysis patients. <i>Nephrol Dial Transplant</i>. 2019;34
(10):1766-1772. doi: 10.1093/ndt/gfy166.<span class3D"pubmed-id"> [PubMed 
<a id3D"29992286" target3D"_blank" href3D"https://www.uptodate.com/conte
nts/ertapenem-drug-information/abstract-text/29992286/pubmed">29992286</a>]
</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-24501388">
                 20
                     <a name3D"24501388"></a>Hsu AJ, Tamma PD. Treatment o
f multidrug-resistant gram-negative infections in children. <i>Clin Infect 
Dis</i>. 2014;58(10):1439-1448.<span class3D"pubmed-id"> [PubMed <a id3D"
24501388" target3D"_blank" href3D"https://www.uptodate.com/contents/ertap
enem-drug-information/abstract-text/24501388/pubmed">24501388</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Invanz.1">
                 20
                     <a name3D"Invanz.1"></a>Invanz (ertapenem) [prescribi
ng information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; November 2022.</d
iv>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Invanz.3">
                 20
                     <a name3D"Invanz.3"></a>Invanz (ertapenem) [product m
onograph]. Kirkland, Quebec, Canada: Merck Canada Inc; June 2022.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-17182989">
                 20
                     <a name3D"17182989"></a>Itani KM, Wilson SE, Awad SS,
 Jensen EH, Finn TS, Abramson MA. Ertapenem versus cefotetan prophylaxis in
 elective colorectal surgery. <i>N Engl J Med</i>. 2006;355(25):2640-2651. 
doi:10.1056/NEJMoa054408<span class3D"pubmed-id"> [PubMed <a id3D"1718298
9" target3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-dr
ug-information/abstract-text/17182989/pubmed">17182989</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-10891521">
                 20
                     <a name3D"10891521"></a>Ito S. Drug therapy for breas
t-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class3D"pu
bmed-id"> [PubMed <a id3D"10891521" target3D"_blank" href3D"https://www.
uptodate.com/contents/ertapenem-drug-information/abstract-text/10891521/pub
med">10891521</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-16225376">
                 20
                     <a name3D"16225376"></a>Keating GM and Perry CM. Erta
penem: a review of its use in the treatment of bacterial infections. <i>Dru
gs.</i> 2005;65(15):2151-2178.<span class3D"pubmed-id"> [PubMed <a id3D"1
6225376" target3D"_blank" href3D"https://www.uptodate.com/contents/ertape
nem-drug-information/abstract-text/16225376/pubmed">16225376</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-31863282">
                 20
                     <a name3D"31863282"></a>Kennedy KE, Teng C, Patek TM,
 Frei CR. Hypoglycemia associated with antibiotics alone and in combination
 with sulfonylureas and meglitinides: an epidemiologic surveillance study o
f the FDA Adverse Event Reporting System (FAERS) [published online December
 20, 2019]. <i>Drug Saf</i>. 2019;10.<span class3D"pubmed-id"> [PubMed <a 
id3D"31863282" target3D"_blank" href3D"https://www.uptodate.com/contents
/ertapenem-drug-information/abstract-text/31863282/pubmed">31863282</a>]</s
pan>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-klompas.2019">
                 20
                     <a name3D"klompas.2019"></a>Klompas M. Treatment of h
ospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed
. UpToDate. Waltham, MA: UpToDate Inc. <a target3D"_blank" href3D"http://
www.uptodate.com/">http://www.uptodate.com</a>. Accessed January 20, 2022.<
/div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-25487647">
                 20
                     <a name3D"25487647"></a>Lee KH, Ueng YF, Wu CW, Chou 
YC, Ng YY, Yang WC. The recommended dose of ertapenem poses a potential ris
k for central nervous system toxicity in haemodialysis patients - case repo
rts and literature reviews. <i>J Clin Pharm Ther</i>. 2015a;40(2):240-244. 
doi:10.1111/jcpt.12239<span class3D"pubmed-id"> [PubMed <a id3D"25487647"
 target3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-drug
-information/abstract-text/25487647/pubmed">25487647</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-26278576">
                 20
                     <a name3D"26278576"></a>Lee S, Prasad P, Lin M, Garri
tson S, Nichols A, Liu C. Ertapenem prophylaxis associated with an increase
d risk of <i>Clostridium difficile</i> infection among surgical patients. <
i>Infect Control Hosp Epidemiol</i>. 2015b;36(11):1351-1354. doi:10.1017/ic
e.2015.193<span class3D"pubmed-id"> [PubMed <a id3D"26278576" target3D"_
blank" href3D"https://www.uptodate.com/contents/ertapenem-drug-information
/abstract-text/26278576/pubmed">26278576</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-31398843">
                 20
                     <a name3D"31398843"></a>Lee Y, Bradley N. Overview an
d insights into carbapenem allergy. <i>Pharmacy (Basel)</i>. 2019;7(3):110.
 doi:10.3390/pharmacy7030110<span class3D"pubmed-id"> [PubMed <a id3D"313
98843" target3D"_blank" href3D"https://www.uptodate.com/contents/ertapene
m-drug-information/abstract-text/31398843/pubmed">31398843</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-26919659">
                 20
                     <a name3D"26919659"></a>Lewis SJ, Kays MB, Mueller BA
. Use of Monte Carlo simulations to determine optimal carbapenem dosing in 
critically ill patients receiving prolonged intermittent renal replacement 
therapy.<i> J Clin Pharmacol</i>. 2016;56(10):1277-1287. doi: 10.1002/jcph.
727.<span class3D"pubmed-id"> [PubMed <a id3D"26919659" target3D"_blank"
 href3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstr
act-text/26919659/pubmed">26919659</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-22619242">
                 20
                     <a name3D"22619242"></a>Lipsky BA, Berendt AR, Cornia
 PB, et al; Infectious Diseases Society of America. 2012 Infectious Disease
s Society of America clinical practice guideline for the diagnosis and trea
tment of diabetic foot infections. <i>Clin Infect Dis</i>. 2012;54(12):e132
-e173. doi: 10.1093/cid/cis346.<span class3D"pubmed-id"> [PubMed <a id3D"
22619242" target3D"_blank" href3D"https://www.uptodate.com/contents/ertap
enem-drug-information/abstract-text/22619242/pubmed">22619242</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-28085573">
                 20
                     <a name3D"28085573"></a>Mazuski JE, Tessier JM, May A
K, et al. The Surgical Infection Society revised guidelines on the manageme
nt of intra-abdominal infection.<i> Surg Infect (Larchmt)</i>. 2017;18(1):1
-76. doi: 10.1089/sur.2016.261.<span class3D"pubmed-id"> [PubMed <a id3D"
28085573" target3D"_blank" href3D"https://www.uptodate.com/contents/ertap
enem-drug-information/abstract-text/28085573/pubmed">28085573</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-29462280">
                 20
                     <a name3D"29462280"></a>McDonald LC, Gerding DN, John
son S, et al. Clinical practice guidelines for <i>Clostridium difficile</i>
 infection in adults and children: 2017 update by the Infectious Diseases S
ociety of America (IDSA) and Society for Healthcare Epidemiology of America
 (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085
<span class3D"pubmed-id"> [PubMed <a id3D"29462280" target3D"_blank" hre
f3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-
text/29462280/pubmed">29462280</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-19489710">
                 20
                     <a name3D"19489710"></a>Mermel LA, Allon M, Bouza E, 
et al. Clinical practice guidelines for the diagnosis and management of int
ravascular catheter-related infection: 2009 update by the Infectious Diseas
es Society of America [published correction appears in <i>Clin Infect Dis</
i>. 2010;50(7):1079. <i>Clin Infect Dis</i>. 2010;50(3):457]. <i>Clin Infec
t Dis.</i> 2009;49(1):1-45. doi: 10.1086/599376.<span class3D"pubmed-id"> 
[PubMed <a id3D"19489710" target3D"_blank" href3D"https://www.uptodate.c
om/contents/ertapenem-drug-information/abstract-text/19489710/pubmed">19489
710</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-31573350">
                 20
                     <a name3D"31573350"></a>Metlay JP, Waterer GW, Long A
C, et al. Diagnosis and treatment of adults with community-acquired pneumon
ia. An official clinical practice guideline of the American Thoracic Societ
y and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i
>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class3D"pubme
d-id"> [PubMed <a id3D"31573350" target3D"_blank" href3D"https://www.upt
odate.com/contents/ertapenem-drug-information/abstract-text/31573350/pubmed
">31573350</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-21449629">
                 20
                     <a name3D"21449629"></a>Miller AD, Ball AM, Bookstave
r PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agen
ts: mechanism of action, seizure rates, and clinical considerations. <i>Pha
rmacotherapy</i>. 2011;31(4):408-423. doi:10.1592/phco.31.4.408<span class
3D"pubmed-id"> [PubMed <a id3D"21449629" target3D"_blank" href3D"https:
//www.uptodate.com/contents/ertapenem-drug-information/abstract-text/214496
29/pubmed">21449629</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Moehring.1">
                 20
                     <a name3D"Moehring.1"></a>Moehring R, Anderson DV. Gr
am-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham,
 MA: UpToDate Inc. <a target3D"_blank" href3D"http://www.uptodate.com/">h
ttp://www.uptodate.com</a>. Accessed February 25, 2019.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Munoz-Price.1">
                 20
                     <a name3D"Munoz-Price.1"></a>Munoz-Price LS. Extended
-spectrum beta-lactamases. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc
. <a target3D"_blank" href3D"http://www.uptodate.com/">http://www.uptodat
e.com</a>. Accessed June 6, 2022.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-NICE.1">
                 20
                     <a name3D"NICE.1"></a>National Institute for Health a
nd Care Excellence. Drug allergy: diagnosis and management. Published Septe
mber 3, 2014. Accessed July 19, 2023. https://www.nice.org.uk/guidance/cg18
3
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-15150180">
                 20
                     <a name3D"15150180"></a>Nix DE, Majumdar AK, and DiNu
bile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview fo
r clinicians. <i>J Antimicrob Chemother.</i> 2004;53(suppl 2):ii23-ii28.<sp
an class3D"pubmed-id"> [PubMed <a id3D"15150180" target3D"_blank" href
3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-t
ext/15150180/pubmed">15150180</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-28947625">
                 20
                     <a name3D"28947625"></a>Nix DE, Mayersohn M, Erstad B
L. Should estimates of glomerular filtration rate and creatinine clearance 
be indexed to body surface area for drug dosing? <i>Am J Health Syst Pharm<
/i>. 2017;74(21):1814-1819. doi:10.2146/ajhp160467<span class3D"pubmed-id"
> [PubMed <a id3D"28947625" target3D"_blank" href3D"https://www.uptodate
.com/contents/ertapenem-drug-information/abstract-text/28947625/pubmed">289
47625</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-9736564">
                 20
                     <a name3D"9736564"></a>Odenholt I, LC3B6wdin E, Car
s O. In vitro pharmacodynamic studies of L-749,345 in comparison with imipe
nem and ceftriaxone against gram-positive and gram-negative bacteria. <i>An
timicrob Agents Chemother</i>. 1998;42(9):2365-2370. doi:10.1128/AAC.42.9.2
365<span class3D"pubmed-id"> [PubMed <a id3D"9736564" target3D"_blank" h
ref3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstrac
t-text/9736564/pubmed">9736564</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-osmon.2019">
                 20
                     <a name3D"osmon.2019"></a>Osmon DR, Tande AJ. Osteomy
elitis in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate I
nc. <a target3D"_blank" href3D"http://www.uptodate.com/">http://www.uptod
ate.com</a>. Accessed May 29, 2019.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-23223583">
                 20
                     <a name3D"23223583"></a>Osmon DR, Berbari EF, Berendt
 AR, et al; Infectious Diseases Society of America. Diagnosis and managemen
t of prosthetic joint infection: clinical practice guidelines by the Infect
ious Diseases Society of America. <i>Clin Infect Dis</i>. 2013;56(1):e1-e25
. doi: 10.1093/cid/cis803.<span class3D"pubmed-id"> [PubMed <a id3D"23223
583" target3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-
drug-information/abstract-text/23223583/pubmed">23223583</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-35708330">
                 20
                     <a name3D"35708330"></a>Park JJ, Jung EJ, Kim JY, Seo
 YB, Lee J, Jung Y. Thirty-day mortality rates in patients with extended-sp
ectrum CEB2-lactamase-producing <i>Enterobacterales</i> bacteremia receiv
ing ertapenem versus other carbapenems. <i>Antimicrob Agents Chemother</i>.
 2022;66(7):e0028722. doi:10.1128/aac.00287-22<span class3D"pubmed-id"> [P
ubMed <a id3D"35708330" target3D"_blank" href3D"https://www.uptodate.com
/contents/ertapenem-drug-information/abstract-text/35708330/pubmed">3570833
0</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Pemberton.1">
                 20
                     <a name3D"Pemberton.1"></a>Pemberton JH. Acute coloni
c diverticulitis: Medical management. Post TW, ed. UpToDate. Waltham, MA: U
pToDate Inc. <a target3D"_blank" href3D"http://www.uptodate.com/">http://
www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-24429437">
                 20
                     <a name3D"24429437"></a>Roberts JA, Paul SK, Akova M,
 et al; DALI Study. DALI: defining antibiotic levels in intensive care unit
 patients: are current CEB2-lactam antibiotic doses sufficient for critic
ally ill patients?<i> Clin Infect Dis</i>. 2014;58(8):1072-1083. doi:10.109
3/cid/ciu027<span class3D"pubmed-id"> [PubMed <a id3D"24429437" target3D
"_blank" href3D"https://www.uptodate.com/contents/ertapenem-drug-informati
on/abstract-text/24429437/pubmed">24429437</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-24180646">
                 20
                     <a name3D"24180646"></a>Romano A, Gaeta F, Valluzzi R
L, et al. Absence of cross-reactivity to carbapenems in patients with delay
ed hypersensitivity to penicillins. <i>Allergy</i>. 2013;68(12):1618-1621. 
doi:10.1111/all.12299<span class3D"pubmed-id"> [PubMed <a id3D"24180646" 
target3D"_blank" href3D"https://www.uptodate.com/contents/ertapenem-drug-
information/abstract-text/24180646/pubmed">24180646</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-25992746">
                 20
                     <a name3D"25992746"></a>Sawyer RG, Claridge JA, Nathe
ns AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrob
ial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21)
:1996-2005. doi:10.1056/NEJMoa1411162<span class3D"pubmed-id"> [PubMed <a 
id3D"25992746" target3D"_blank" href3D"https://www.uptodate.com/contents
/ertapenem-drug-information/abstract-text/25992746/pubmed">25992746</a>]</s
pan>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-26339470">
                 20
                     <a name3D"26339470"></a>Schrijvers R, Gilissen L, Chi
riac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersen
sitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy<
/i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class3D"pubmed-id"> [Pu
bMed <a id3D"26339470" target3D"_blank" href3D"https://www.uptodate.com/
contents/ertapenem-drug-information/abstract-text/26339470/pubmed">26339470
</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-29053792">
                 20
                     <a name3D"29053792"></a>Shane AL, Mody RK, Crump JA, 
et al. 2017 Infectious Diseases Society of America clinical practice guidel
ines for the diagnosis and management of infectious diarrhea. <i>Clin Infec
t Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class3D"pubmed
-id"> [PubMed <a id3D"29053792" target3D"_blank" href3D"https://www.upto
date.com/contents/ertapenem-drug-information/abstract-text/29053792/pubmed"
>29053792</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-20034345">
                 20
                     <a name3D"20034345"></a>Solomkin JS, Mazuski JE, Brad
ley JS, et al. Diagnosis and management of complicated intra-abdominal infe
ction in adults and children: guidelines by the Surgical Infection Society 
and the Infectious Diseases Society of America [published correction appear
s in <i>Clin Infect Dis</i>. 2010;50(12):1695]. <i>Clin Infect Dis</i>. 201
0;50(2):133-164. doi: 10.1086/649554.<span class3D"pubmed-id"> [PubMed <a 
id3D"20034345" target3D"_blank" href3D"https://www.uptodate.com/contents
/ertapenem-drug-information/abstract-text/20034345/pubmed">20034345</a>]</s
pan>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Spelman.1">
                 20
                     <a name3D"Spelman.1"></a>Spelman D, Baddour LM. Acute
 cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Wal
tham, MA: UpToDate Inc. <a target3D"_blank" href3D"http://www.uptodate.co
m/">http://www.uptodate.com</a>. Accessed July 12, 2022.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Stevens.1">
                 20
                     <a name3D"Stevens.1"></a>Stevens DL, Baddour LM. Necr
otizing soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDat
e Inc. <a target3D"_blank" href3D"http://www.uptodate.com/">http://www.up
todate.com</a>. Accessed July 12, 2022.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-24947530">
                 20
                     <a name3D"24947530"></a>Stevens DL, Bisno AL, Chamber
s HF, et al. Practice guidelines for the diagnosis and management of skin a
nd soft tissue infections: 2014 update by the Infectious Diseases Society o
f America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59
(2):e10-52. doi: 10.1093/cid/ciu296.<span class3D"pubmed-id"> [PubMed <a i
d3D"24947530" target3D"_blank" href3D"https://www.uptodate.com/contents/
ertapenem-drug-information/abstract-text/24947530/pubmed">24947530</a>]</sp
an>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-21653301">
                 20
                     <a name3D"21653301"></a>Stevens V, Dumyati G, Fine LS
, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time a
nd the risk of <i>Clostridium difficile</i> infection. <i>Clin Infect Dis</
i>. 2011;53(1):42-48. doi:10.1093/cid/cir301<span class3D"pubmed-id"> [Pub
Med <a id3D"21653301" target3D"_blank" href3D"https://www.uptodate.com/c
ontents/ertapenem-drug-information/abstract-text/21653301/pubmed">21653301<
/a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-7797443">
                 20
                     <a name3D"7797443"></a>Sunagawa M, Matsumura H, Sumit
a Y, Nouda H. Structural features resulting in convulsive activity of carba
penem compounds: effect of C-2 side chain. <i>J Antibiot (Tokyo)</i>. 1995;
48(5):408-416. doi:10.7164/antibiotics.48.408<span class3D"pubmed-id"> [Pu
bMed <a id3D"7797443" target3D"_blank" href3D"https://www.uptodate.com/c
ontents/ertapenem-drug-information/abstract-text/7797443/pubmed">7797443</a
>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-28203577">
                 20
                     <a name3D"28203577"></a>Sutton SS, Jumper M, Cook S, 
Edun B, Wyatt MD. Ertapenem-induced encephalopathy in a patient with normal
 renal function. <i>J Investig Med High Impact Case Rep</i>. 2017;5(1):2324
709616689376. doi:10.1177/2324709616689376<span class3D"pubmed-id"> [PubMe
d <a id3D"28203577" target3D"_blank" href3D"https://www.uptodate.com/con
tents/ertapenem-drug-information/abstract-text/28203577/pubmed">28203577</a
>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-31527026">
                 20
                     <a name3D"31527026"></a>Ueng YF, Wang HJ, Wu SC, Ng Y
Y. A practical thrice weekly ertapenem in hemodialysis patients. <i>Antimic
rob Agents Chemother</i>. 2019;63(12):e01427-19. doi:10.1128/AAC.01427-19<s
pan class3D"pubmed-id"> [PubMed <a id3D"31527026" target3D"_blank" href
3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-t
ext/31527026/pubmed">31527026</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-27216385">
                 20
                     <a name3D"27216385"></a>Vardakas KZ, Trigkidis KK, Bo
ukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following sy
stemic antibiotic administration in randomised controlled trials: a systema
tic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-
10. doi:10.1016/j.ijantimicag.2016.03.008<span class3D"pubmed-id"> [PubMed
 <a id3D"27216385" target3D"_blank" href3D"https://www.uptodate.com/cont
ents/ertapenem-drug-information/abstract-text/27216385/pubmed">27216385</a>
]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Vollmer.1">
                 20
                     <a name3D"Vollmer.1"></a>Vollmer CM Jr, Zakko SF, Afd
hal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. 
Waltham, MA: UpToDate Inc. <a target3D"_blank" href3D"http://www.uptodate
.com/">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-29272341">
                 20
                     <a name3D"29272341"></a>Watson T, Hickok J, Fraker S,
 Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-
onset <i>Clostridium difficile</i> infections in a large healthcare system.
 <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<spa
n class3D"pubmed-id"> [PubMed <a id3D"29272341" target3D"_blank" href3D
"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text
/29272341/pubmed">29272341</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-15150185">
                 20
                     <a name3D"15150185"></a>Wells WG, Woods GL, Jiang Q, 
Gesser RM. Treatment of complicated urinary tract infection in adults: comb
ined analysis of two randomized, double-blind, multicentre trials comparing
 ertapenem and ceftriaxone followed by appropriate oral therapy. <i>J Antim
icrob Chemother</i>. 2004;53(suppl 2):ii67-ii74. doi:10.1093/jac/dkh208<spa
n class3D"pubmed-id"> [PubMed <a id3D"15150185" target3D"_blank" href3D
"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text
/15150185/pubmed">15150185</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-Weintrob.1">
                 20
                     <a name3D"Weintrob.1"></a>Weintrob AC, Sexton DJ. Cli
nical manifestations, diagnosis, and management of diabetic infections of t
he lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a 
target3D"_blank" href3D"http://www.uptodate.com/">http://www.uptodate.com
</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-22579271">
                 20
                     <a name3D"22579271"></a>Wen MJ, Sung CC, Chau T, Lin 
SH. Acute prolonged neurotoxicity associated with recommended doses of erta
penem in 2 patients with advanced renal failure. <i>Clin Nephrol</i>. 2013;
80(6):474-478. doi:10.5414/CN107247<span class3D"pubmed-id"> [PubMed <a id
3D"22579271" target3D"_blank" href3D"https://www.uptodate.com/contents/e
rtapenem-drug-information/abstract-text/22579271/pubmed">22579271</a>]</spa
n>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-23400916">
                 20
                     <a name3D"23400916"></a>Wiskirchen DE, Housman ST, Qu
intiliani R, Nicolau DP, Kuti JL. Comparative pharmacokinetics, pharmacodyn
amics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-m
inute infusion versus the standard 30-minute infusion in healthy adult volu
nteers. <i>Pharmacotherapy</i>. 2013;33(3):266-274. doi: 10.1002/phar.1197.
<span class3D"pubmed-id"> [PubMed <a id3D"23400916" target3D"_blank" hre
f3D"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-
text/23400916/pubmed">23400916</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-WHO.1">
                 20
                     <a name3D"WHO.1"></a>World Health Organization (WHO).
 Breastfeeding and maternal medication, recommendations for drugs in the el
eventh WHO model list of essential drugs. 2002. Available at http://www.who
.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class3D"reference">
                  Xuan D, Banevicius M, Capitano B, Kim MK, Nightingale C, 
Nicolau D. Pharmacodynamic assessment of ertapenem (MK-0826) against Strept
ococcus pneumoniae in a murine neutropenic thigh infection model. <i>Antimi
crob Agents Chemother.</i> 2002;46(9):2990-2995. doi:10.1128/aac.46.9.2990-
2995.2002<span class3D"pubmed-id"> [PubMed <a id3D"12183258" target3D"_b
lank" href3D"https://www.uptodate.com/contents/ertapenem-drug-information/
abstract-text/12183258/pubmed">12183258</a>]</span>
                  </div>
</li>
<li>
<div class3D"reference" id3D"lexi-content-ref-30535100">
                 20
                     <a name3D"30535100"></a>Yahav D, Franceschini E, Kopp
el F, et al; Bacteremia Duration Study Group. Seven versus fourteen days of
 antibiotic therapy for uncomplicated gram-negative bacteremia: a non-infer
iority randomized controlled trial [published online December 11, 2018]. <i
>Clin Infect Dis.</i> doi: 10.1093/cid/ciy1054.<span class3D"pubmed-id"> [
PubMed <a id3D"30535100" target3D"_blank" href3D"https://www.uptodate.co
m/contents/ertapenem-drug-information/abstract-text/30535100/pubmed">305351
00</a>]</span>
                  </div>
</li></ol></div><div id3D"topicVersionRevision">Topic 8675 Version 337.0</
div></div>
                                                              </div>
                </div>
           20
        </section>
           20
               20
    </section>
<!-- End Main Menu Area -->

<!-- Start Search Popup Area -->
<div id3D"search-area">
    <button type3D"button" class3D"close">C397</button>
    <form action3D"search" method3D"get">
        <div class3D"row">
            <div class3D"col-md-5 col-5">
                <input name3D"title" type3D"search" required3D"" placeho
lder3D"EFBAB3EFBA8EEFBBA3EFBA8EEFBBA7EFBBAA EFBA81EF
BBA7EFBBBCEFAFBEEFBBA6 EFBBA3EFBAAAEFAFBEEFBBA0EF
AFBFEFBA90">
            </div>
            <div class3D"col-md-4 col-4">
                <select name3D"content" id3D"roundText" class3D"form-con
trol round addpo" required3D"">
                                            <option value3D"book">DAA9
D8AAD8A7D8A8D8AED8A7D986D987 D8A2D986D984D8A7DB8C
D986 D988 DA86D8A7D9BEDB8C D8B2D8A8D8A7D986 D8A7D8
B5D984DB8C</option>
                                            <option value3D"printedBook"> 
DAA9D8AAD8A7D8A8 DA86D8A7D9BEDB8C D981D8A7D8B1D8B3
DB8C</option>
                                            <option value3D"journal">DA
98D988D8B1D986D8A7D984</option>
                                            <option value3D"medicalMovies"
>D988DB8CD8AFD98AD988 D8A2D985D988D8B2D8B4</option>
                                            <option value3D"uptodate">D8
A2D9BED8AAD988D8AFDB8CD8AA</option>
                                            <option value3D"persianBook">
DAA9D8AAD8A7D8A8D8AED8A7D986D987 D8A2D986D984D8A7
DB8CD986 D981D8A7D8B1D8B3DB8C</option>
                                    </select>
            </div>
            <div class3D"col-md-3 col-3" 3D"margin-top: 0;">
                <button type3D"submit" class3D"btn btn-primary">D8ACD8
B3D8AAD8ACD988</button>
            </div>
        </div>
    </form>
</div>
<footer class3D"footer-area">
    <div class3D"container">
        <div class3D"row">
            <div class3D"col-lg-4 col-md-6">
                <div class3D"single-footer">
                    <p> EFBA97EFBBA4EFBA8EEFBAB1 EFBA91EF
BA8EEFBBA3EFBA8E</p>

                    <ul class3D"footer-contact-info">
                                                    <li>D8AAD987D8B1
D8A7D986, D8B4D987D8B1DAA9 D8B1D8A7D987 D8A2D987D9
86, D8B6D984D8B9 D8B4D985D8A7D984 D8B4D8B1D982DB8C 
D8AFD8B1DB8CD8A7DA86D987 DA86DB8CD8AADAAFD8B1, D985
DB8CD8AFD8A7D986 D8B3D8A7D8ADD984, D8B4D987D8B1DAA9
 D8B3D8A7D8ADD984, DAA9D988DA86D987 D986D8ACD985, D9
BED984D8A7DAA9 DBB4DBB8</li>
                            <li>
                                D8AED8B7 D988DB8CDA98D987
                                <a href3D"tel:+989900994810">DBB0DBB9
DBB9DBB0DBB0DBB9DBB9DBB4DBB8DBB1DBB0</a>
                                <a href3D"tel:+989900994820">DBB0DBB9
DBB9DBB0DBB0DBB9DBB9DBB4DBB8DBB2DBB0</a>
                                <a href3D"tel:+989900994830">DBB0DBB9
DBB9DBB0DBB0DBB9DBB9DBB4DBB8DBB3DBB0</a>
                                <a href3D"tel:+982144755900">DBB0DBB2
DBB1DBB4DBB4DBB7DBB5DBB5DBB9DBB0DBB0</a>

                            </li>
                                                <li><a href3D"mailto:info@
medilib.ir">info@medilib.ir</a></li>
                    </ul>

                    <ul class3D"social">
                        <li><a href3D"https://www.facebook.com/sharer.php?
u3D/d/html/8675" target3D"_blank"><i class3D"ic
ofont-facebook }}"></i></a></li>
                        <li>
                            <a href3D"https://twitter.com/share?url3D3Dh
ttps://medilib.ir/uptodate/show/8675&amp;text3Duptodate
/show/8675&amp;hashtags3D/d/html/8675" target3D"
_blank"><i class3D"icofont-twitter"></i></a></li>
                        <li><a href3D"/d/html/867
5#"><i class3D"icofont-instagram"></i></a></li>
                        <li><a href3D"http://www.linkedin.com/shareArticle
?mini3Dtrue&amp;url3D/d/html/8675" target3D"_bl
ank"><i class3D"icofont-linkedin"></i></a></li>
                        <li><a href3D"tg://share/url?url3Dhttps://medilib
.ir/uptodate/show/8675&amp;text3D/d/html/8675;" t
arget3D"_blank"><i class3D"icofont-telegram"></i></a></li>
                        <li><a href3D"https://api.whatsapp.com/send?text
3D/d/html/8675" data-action3D"share/whatsapp/sha
re" target3D"_blank"><i class3D"icofont-whatsapp"></i></a>
                        </li>
                        <li><a href3D"mailto:?subject3Dhttps://medilib.ir
/uptodate/show/8675&amp;body3D/d/html/8675" targe
t3D"_blank"><i class3D"icofont-mail"></i></a></li>
                    </ul>
                </div>
            </div>

           20

            <div class3D"col-lg-4 col-md-6">
                <div class3D"single-footer">
                    <p>EFBBA3EFBBA8EFBBAE EFBBABEFBA8E</p>

                    <ul class3D"list">
                        <li id3D"footerPromptElement">
                            <a class3D"prompt__install">
                                D8A7D8B6D8A7D981D987 DAA9D8B1
D8AFD986 D985D8AFDB8CD984DB8CD8A8 D8A8D987 D8B5D981
D8ADD987 D8A7D8B5D984DB8C
                            </a>
                        </li>
                        <li>
                            <a href3D"apps/MediLib.apk"
>
                                D8AFD8A7D986D984D988D8AF D8A7
D9BED984DB8CDAA9DB8CD8B4D986 D8A7D986D8AFD8B1D988
DB8CD8AF
                            </a>
                        </li>
                        <li>
                            <a href3D"Lib">
                                EFAE90EFBA98EFBA8EEFBA91EFBA
A8EFBA8EEFBBA7EFBBAA EFBA81EFBBA7EFBBBCEFAFBEEFBB
A6
                            </a>
                        </li>
                        <li>
                            <a href3D"UpToDate">
                                EFBA81EFAD98EFBA98EFBBAEEFBA
A9EFAFBEEFBA96
                            </a>
                        </li>
                        <li>
                            <a href3D"Journal">
                                EFAE8AEFBBADEFBAADEFBBA7EFBA
8EEFBB9D
                            </a>
                        </li>
                        <li>
                            <a href3D"Learn">
                                D988DB8CD8AFDB8CD988DB8C D8A2
D985D988D8B2D8B4DB8C
                            </a>
                        </li>
                        <li>
                            <a href3D"Recruitment">
                                D8A7D8B3D8AAD8AED8AFD8A7D985
                            </a>
                        </li>
                        <li>
                            <a href3D"aboutUs">
                                D8AFD8B1D8A8D8A7D8B1D987 D985
D8A7
                            </a>
                        </li>
                        <li>
                            <a href3D"contactUs">
                                 EFBA97EFBBA4EFBA8EEFBAB1 EF
BA91EFBA8EEFBBA3EFBA8E
                            </a>
                        </li>
                    </ul>
                </div>
            </div>

            <div class3D"col-lg-4 col-md-6">
                <div class3D"single-footer">
                    <p>EFAE90EFBA8EEFBAADEFBA95 EFBBADEFAF
BEEFBAB0EFAFBEEFBA96 D8A7EFBB9FEFAE91EFBA98EFBAAE
EFBBADEFBBA7EFAFBFEFAE91EFAFBD</p>

                    <ul class3D"list">
                        <li 3D"font-size: 11px;">EFBA9FEFBBAC
EFBA96 EFBAA9EFBAADEFAFBEEFBA8EEFBB93EFBA96 EFAE90
EFBA8EEFBAADEFBA95 EFBBADEFAFBEEFBAB0EFAFBEEFBA96 
D8A7EFBB9FEFAE91EFBA98EFBAAEEFBBADEFBBA7EFAFBFEFAE
91EFAFBD EFAE90EFBAAA EFBAAFEFAFBEEFBAAE EFBAADD8A7
 D8A7EFBAB3EFAE91EFBBA6 EFBBA7EFBBA4EFBA8EEFAFBEEF
AFBFEFBAAA</li>
                                                    <li><img src3D"https:/
/medilib.ir/siteui/app-assets/img/qrir.png" alt3D""></li>
                                            </ul>
                </div>
            </div>


        </div>
    </div>

    <div class3D"copyright-area">
        <div class3D"container">
            <div class3D"row">
                <div class3D"col-lg-7 col-md-7">
                    <p>EFBA97EFBBA4EFBA8EEFBBA3EFBBB2 EFBA
A3EFBB98EFBBAEEFBB95 EFBA91EFBAAED8A7EFBBB1 EFBBA3
EFBAAAEFBBB3EFBBA0EFBBB4EFBA90 EFBBA3EFBAA4EFBB94
EFBBAEEFBB85 D8A7EFBAB3EFBA96 2024 D88C EFBB83EFBAAE
D8A7EFBAA3EFBBB2 EFBBAD EFAD98EFBBB4EFBA8EEFBAA9EF
BBA9 EFBAB3EFBA8EEFBAAFEFBBB1 EFBA97EFBBAEEFBAB3EF
BB82 EFBAA9EFAD98EFBA8EEFBAADEFBA97EFBBA4EFBA8EEF
BBA5 D8A7EFBBA7EFBB94EFBBAEEFBAADEFBBA3EFBA8EEFBA
97EFBBB4EFBB9A MediLib <i class3D"icofont-copyright"></i></p>
                </div>

                <div class3D"col-lg-5 col-md-5">

                </div>
            </div>
        </div>
    </div>
</footer>
<!-- End Footer Area -->

<!-- Back to top -->
<div class3D"pwaprompt">
    <p class3D"text-body text-capitalize text-center">D8A2DB8CD8A7 
D985DB8C D8AED988D8A7D987DB8CD8AF D985D8AFDB8CD984
DB8CD8A8 D8B1D8A7 D8A8D987 D8B5D981D8ADD987 D8A7D8
B5D984DB8C D8AED988D8AF D8A7D8B6D8A7D981D987 DAA9D9
86DB8CD8AFD89F</p>
    <button type3D"button" class3D"btn-sm btn-info prompt__install">D8
A8D984D987 D984D8B7D981D8A7</button>
    <button type3D"button" class3D"btn-sm btn-warning prompt__close">D9
86D987 D985D985D986D988D986</button>
</div>
<a class3D"scrolltop" href3D"/d/html/8675#top" s
tyle3D"display: inline;"><i class3D"icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->

<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->


<div class3D"modal fade" id3D"iphoneAddToHomeScreen" tabindex3D"-1" role
3D"dialog" aria-labelledby3D"iphoneAddToHomeScreenLabel" aria-hidden3D"t
rue">
    <div class3D"modal-dialog" role3D"document" 3D"max-width: 900px
">
        <div class3D"modal-content" 3D"direction: rtl;">
            <div class3D"modal-header">
                <h5 class3D"modal-title" id3D"iphoneAddToHomeScreenLabel"
>D8A7D8B6D8A7D981D987 DAA9D8B1D8AFD986 D985D8AFDB8C
D984DB8CD8A8 D8A8D987 D8B5D981D8ADD987 D8A7D8B5D984
DB8C</h5>
            </div>
            <img src3D"assets/img/iphoneAddToHomeScreen
Label.webp" alt3D"iphoneAddToHomeScreen">
        </div>
    </div>
</div>

 20
 20



</body></html>